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Abstract 
Aims 
The aim of this process improvement was to introduce routine antenatal anti-D prophylaxis 
(RAADP) injection at 28 weeks gestation to all Rhesus (Rh-D) negative women attending 
Cavan General Maternity services.  This was initially achieved by outlining objectives which 
gave focus to the project. These objectives facilitated the development of the subsequent 
business case, implementation plan and evaluation process. 
Rationale 
The introduction of routine antenatal anti-D prophylaxis was in order to be fully compliant with 
the National Guideline recommendations by the Clinical Care Programme in Obstetrics and 
Gynaecology. 
Change Process 
The writer introduced this change using the Health Service Executive Organisational 
Development Model as a guiding document. This provided a structured and systematic 
approach which informed the change process. The four stages of change included initiation, 
planning, implementation and mainstreaming. 
Evaluation 
The evaluation of the project revealed benefits from training with excellent practice and 
service delivery. Compliance with routine antenatal anti-D prophylaxis was successful as 
evidenced by the laboratory audit carried out following implementation of the project. 
Results and Conclusion 
All women at Cavan General Hospital are now offered routine antenatal anti-D prophylaxis 
(RAADP) at 28 weeks gestation. There is a need to further develop the service in order to 
provide RAADP as an off-site amenity. 
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1.1 Introduction 
 
This dissertation proposes to guide the maternity services at Cavan General Hospital in 
relation to the introduction of routine antenatal anti-D prophylaxis (RAADP) injection to all 
Rhesus Negative (Rh-D) women attending the service. Introducing change in any 
organisation, but particularly a healthcare setting, requires the use of a structured process 
that provides clarity and engagement for all those who not only work in the service, but to 
those who have access to it (HSE, 2008). The writer will use the Health Service Executive 
(HSE) Organisational Development (OD) Change Model to provide this structure. This model 
is based on an organisational development approach which focuses on the people aspects of 
change. It also uses a project management style in order to bring structure and discipline to 
the process (HSE, 2008). The HSE OD Change Model adapts an action research approach 
which works well in a healthcare setting as it was developed to improve the experience of 
patient and service users, help staff and teams actively work together to improve services and 
provide a consistent approach to change across the system (HSE, 2008).  
In order to understand why prophylactic anti-D is recommended in pregnancy it is first 
necessary to briefly explain the role of the placenta in pregnancy. The placenta (also known 
as the afterbirth) is a remarkable endocrine organ which connects the developing fetus 
to the uterine wall. It carries out the functions which the fetus is unable to perform for itself 
during intrauterine life. It plays a vital role in the transfer of oxygen and nutrients to the fetus 
and allows for waste elimination and gas exchange via the mother's blood supply. It also 
helps fight against internal infection (Fox & Neil, 2007). The placenta also produces hormones 
which help support the on-going pregnancy. For the most part it also acts as a barrier to fetal 
blood entering the maternal circulation (Marshall & Raynor, 2014), however during pregnancy 
or birth, fetomaternal haemorrhage can occur. This can cause small amounts of fetal blood to 
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cross the placenta and enter the mothers’ blood. If the mother is Rh-D negative and the baby 
is Rhesus positive than this is known as a potential sensitizing event (PSE) (Appendix 1). As 
a result of this the maternal immune system can become sensitised against aspects of the 
baby’s blood group (MacDonald & Magill-Cuerden, 2011). This has implications for future 
pregnancies. 
Currently the organisation provides anti-D immunoglobin to all Rh-D negative women for any 
PSE and following delivery of a Rhesus positive baby. A total of 241 (14%) women attending 
Cavan General’s maternity services in 2014 were Rh-D negative.  
1.2 Organisational Context 
 
The writer works in a rural Maternity Unit that is attached to Cavan General Hospital. 
Approximately 2,000 births occur in this unit on a yearly basis. The unit has three Obstetric 
Consultants and a co-located Midwifery Led Unit. These services provide antenatal, intranatal 
and postnatal care for all pregnant women attending the service. Antenatal care is also 
provided in outreach clinics at Monaghan Hospital. The Maternity Unit delivers Level 2 
(Appendix 2) services to the surrounding areas of Cavan, Monaghan, Sligo, Leitrim and parts 
of Meath. 
In 2012 the National Clinical Care Programme in Obstetrics launched a guideline (Fitzgerald 
& Conneally, 2012) recommending the introduction of RAADP at 28 weeks for all Rh-D 
negative women. Supporting and implementing this recommendation for change will be the 
subject of this dissertation as the writer proposes to introduce RAADP as a quality 
improvement initiative in her hospital. 
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1.3 Rationale 
The rationale for choosing this proposal evolved from the publication of this National 
Guideline (Fitzgerald & Conneally, 2012). Currently Rh-D negative women attending the 
service do not receive routine antenatal anti-D prophylactically (RAADP). There is a growing 
body of literature that recognises the importance of administering RAADP. The purpose of 
this project is to introduce RAADP to all Rh-D negative women attending Cavan General, in 
order to be fully compliant with the national guideline (Fitzgerald & Conneally, 2012). 
1.4 Aims and Objectives 
The writer aims to introduce the administration of RAADP to all non-sensitised Rh-D negative 
women at 28 weeks gestation at Cavan General Hospital. The following is a list of objectives 
to help achieve this. 
1. Establish and implement procedures for the implementation of RAADP by September 
2015. 
2. By October 2015,  all eligible Rh-D negative women will be offered RAADP at 28 
weeks gestation in order to be fully compliant with the National Clinical Care 
Programme guideline (Fitzgerald & Conneally, 2012). 
3. Design and deliver an education programme to support practitioners with implementing 
this service, by January 2016. 
4. Produce a patient information leaflet to be given to all Rh-D negative women prior to 
the administration of RAADP. 
5. Access the effectiveness of this initiative in January 2016 and April 2016. 
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1.5 Role of the Student 
The writer is currently employed in Cavan General Hospital as a Clinical Midwife Manager 
Two (CMM2)  responsible for the management and delivery of the Midwifery Led Service’s 
that are co-located within the main maternity unit. Introducing any process improvement 
within an organisation begins with an understanding of the needs of the service and the 
desire to provide quality to the service users (HSE, 2008). Quality within any healthcare 
setting can be described as a service that gives people what they need, as well as what they 
want, and does so at the lowest possible cost (Ovretveit, 1995). On these grounds, this 
project was proposed and approved by the clinical governance committee and the writer 
became part of the implementation team responsible for the delivery of RAADP to all Rh-D 
negative women at 28 weeks gestation.  
1.6 Summary and Conclusion 
The overall structure of this dissertation is presented in five chapters. The introductory 
chapter provides a brief overview of the mother and baby relationship in utero and why anti-D 
would be required in an antenatal context. The rationale for carrying out the project is outlined 
within the context of the organisation and the aim and specific objectives are set. Chapter 2 
lays down the theoretical dimensions of the literature to provide a more in-depth 
understanding of the evidence surrounding the use of anti D immunoglobulin and its role in 
preventing potential Rh-D sensitisation. The themes explored will inform this process by 
including an explanation of what anti-D is and what is meant by prophylaxis. Further 
exploration of why we need to give prophylactic anti-D and the implications of both giving it, 
and not giving it, are considered. The writer will also explore the value of education and its 
role in supporting this change process. Implications for the project will be outlined and the 
rationale for introducing the use of prophylactic anti-D at 28 weeks gestation. Chapter 3 is 
14 
 
concerned with the methodology used for this project and describes its use in the 
implementation of RAADP. The writer will  use the Health Service Executive Change Model 
(HSE, 2008) to provide this structure to the implementation process. A critical review of this 
change model, both as a tool for implementing change, and its ability to provide clarity to that 
change will be explored. Following delivery of the project the writer will also reflect on the 
experience of introducing change and using the HSE OD model as a guide to manage that 
change within the healthcare setting. Chapter 4 will provide a brief discussion on the 
importance of healthcare evaluation.  The writer will look at the evidence around using audit 
as an evaluation tool. The design of the audit will be based around the objectives in chapter 
one. Three different aspects of the implementation plan will be audited that best reflect the 
objectives of the project. The success of the training programme will be evaluated in two 
separate ways. Assessment of learning will be achieved using post evaluation questionnaires 
following training. An audit of the documentation checklist, designed for use in the project, will 
reflect application of learning to practice. Three months following commencement of the 
project, the writer will perform an initial documentation checklist audit in order to identify if 
there are any training deficits withstanding. Finally the writer will carry out an audit in the 
laboratory to determine did all women who were eligible to receive RAADP offered it, as this 
will be the determinate success of the project. Chapter 5 draws together the overall findings 
of this project. The writer will critically discuss the implementation process and reflect on the 
evaluation findings. Finally the writer will discuss the impact that this process improvement 
has had on the organisation and the contribution it has made on delivering a quality service. 
Recommendations for future improvements will be suggested. 
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Chapter Two:  Literature Review 
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2.1 Introduction 
In pregnancy women who are Rh-D negative require specific antenatal care and monitoring 
(Turner et al., 2012). The use of anti-D in Rh-D negative women within a maternity setting is 
widely accepted and has been administered for over 40 years. The practice however mainly 
focuses on its administration following a potential sensitising event (PSE) (Appendix 1) and 
following the delivery of a Rhesus positive baby. The introduction of prophylactic anti-D to 
reduce the chances of unprovoked sensitisation occurring in pregnancy was first proposed in 
the 1970’s (MacKenzie et al., 2006). The aim of prophylaxis was to further reduce the risk of 
Rh-D immunisation. Rhesus immunisation can have detrimental effects on the fetus and 
newborn. 
Haemolytic disease of the newborn (HDN) due to Rh-D immunisation is an infrequent, but 
severe, complication of pregnancy. HDN is an alloimmune condition that develops in a fetus 
when anti-D IgG molecules produced by the mother pass through the placenta into the fetal 
circulation. The resultant anti-D allioimmunisation (Appendix 3) is a condition which can have 
considerable impact on the life of the unborn infant in subsequent pregnancies. There is a 
growing body of evidence that recognises the importance of the administration of prophylactic 
anti-D in pregnancies where the woman is known to be Rh-D negative to prevent this 
condition.  The purpose of this review is to explore the theoretical dimensions of the research 
and review how the administration of prophylactic anti-D can improve outcomes of Rhesus 
positive babies born to Rh-D negative women. This review will support the writer’s process 
improvement initiative whereby the introduction of prophylactic anti-D in the third trimester of 
pregnancy is established in the organisation.  
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2.2 Search Strategy 
Relevant papers discussing the use of prophylactic anti-D in pregnancy were identified using 
the sources RCSI library, Medline, Cinahl, HSElibrary, Clinical Key, Up-To-Date, Cochrane 
databases and Google scholar. Using Cinahl headings the following terms were used to 
identify suitable articles: “Rho(D) Immune Globulin”, “Rh Isoimmunization – prevention and 
control”, “Infant”, “Newborn”,  “Pregnancy Trimester”, “First” and “Obstetric” as subject 
headings. The database “up-to-date” was used as the writer wanted to review articles from a 
user’s perspective. 
The writer expanded the search using Boolean logic “and”, “or” and “not”. Limiters were used 
to refine the search to peer reviewed, and papers published between 2000 and 2015 were 
considered, with no language restrictions. From the selected articles the writer chose those 
whose main focuses were on the discussion of prophylactic anti-D (RAADP). Articles included 
guidelines, systematic reviews, meta-analyses, prospective studies and cost effectiveness 
analysis studies. Articles that only discussed antenatal post sensitisation administration and 
postnatal administration were excluded from this review and 23 articles in total were used. 
Five key themes emerged and informed the structure of this review. The writer begins with a 
background to help inform the reader as they move through the review. This is followed by an 
overview of anti-D and how it works, discussions around when we need to give it, the 
evidence on the implications for giving it and lastly the importance of the role of education. 
All references obtained were entered into “Mendeley Referencing Manager” computer 
software system and the American Psychological Association (APA) 6th Edition referencing 
was utilised.  
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2.3 Review of Themes 
2.3.1 Background 
In order to better understand the relevance of anti-D it is necessary to give a brief overview of 
the basic physiology of the human blood system and the relationship between the maternal 
and fetal system in pregnancy. Human blood is classified based on two main systems. These 
are the ABO system and the Rhesus (Rh) system (Pilgrim et al., 2009). The Rhesus system 
contains several related proteins, the most relevant one being the Rhesus D (Rh-D) antigen. 
If a woman has this antigen she is classified as Rh-D positive and in its absence she is 
classified as Rh-D negative. The precise function of these antigens are unknown (Urbaniak & 
Greiss, 2000) but it becomes very relevant for women in pregnancy where a Rh-D negative 
mother carry’s a Rh-D positive baby.  
During intrauterine life, the fetal placental circulation operates as a single unit, providing a low 
resistance, high-capacity reservoir in the vascular bed of the placenta (MacDonald & Magill-
Cuerden, 2011). The maternal blood circulates through the placenta enabling the absorption 
of food and oxygen and the absorption of waste products (Marshall et al., 2014).  In the event 
that there is mixing of mothers’ blood with baby’s, the mother develops anti-D IgG antibodies 
in response. While this has little impact on the first pregnancy, the development of anti-D 
antibodies may result in potentially life threatening conditions in subsequent pregnancies 
where the mother carries a Rh-D positive baby.  
2.3.2 What is Anti-D and How Does it Work?  
Anti-D immunoglobulin is a freeze dried concentration of Anti-D Immunoglobulin made from a 
pooled source of human plasma of males and post-menopausal women who are Rh-D 
negative (Crowther et al., 2013). The resultant sterile solution protects against Rh-
sensitisation or allioimmunisation. It is manufactured by a multistep chromatographic 
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procedure. This removes 98% of contaminated proteins leaving only enriched IgG (Stucki et 
al, 2000). This product is stable for three years and is comparable to other anti-D products on 
the market (Stucki et al., 2000). Development of Rh-D immunisation in the 1960’s was based 
on the well-recognised phenomenon of antibody-mediated immune suppression (AIMS). This 
process facilitates specific antibodies to be passively administered that are known to prevent 
active immunisation (Urbaniak & Greiss, 2000). In order to protect against immunisation of 
Rh-D positive cells in the maternal circulation, they must be removed within 5 days of 
administration of anti-D (Kumpel, 2006). 
For treatment, anti-D can be administered by intravenous (IV) or intramuscular (IM) injection. 
When injected into the maternal system anti-D immunoglobulin will “mop up” the circulating 
Rh-D positive red blood cells (Figure 1). This prevents the usual immune response in the 
mother by preventing the development of harmful anti-D antibodies (Koelewijn et al., 2009). 
As a result of this the potential sensitising event (PSE) goes unnoticed by the maternal 
system. 
 
 Figure 1: Image of how Anti-D works 
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2.3.2 Why is Anti-D Given? 
Haemolytic disease of the newborn (HDN) is a disease caused by maternal IgG antibodies 
crossing the placenta, binding to the fetal antigen-positive red blood cells (RBC), and initiating 
their destruction, thereby causing anaemia (Avent & Reid, 2000). Prior to 1970, HDN was a 
significant cause of perinatal mortality and morbidity due to the development of these anti-D 
antibodies secondary to feto-maternal haemorrhage (FMH) occurring in Rh-D negative 
women carrying an Rh-D positive baby. This led to the introduction of post-natal 
immunoprophylaxis and prophylaxis for other potential sensitising events (PSE), with anti-D 
IgG immunoglobulin (Koelewijn et al., 2009). This decreased the incidence of post pregnancy 
Rh-D immunisation from 12-13% to 1-2% (Hartwell, 1998). There is currently sufficient 
evidence demonstrating that by also providing antenatal prophylaxis, the risk of Rh-D 
immunisation in the subsequent pregnancy can drop to a level of below 0.4% (Liumbruno et 
al., 2010). Fyfe et al. (2014) in their scoping review found that despite this the delivery of anti-
D to Rh-D negative pregnant women was suboptimal. 
While haemolytic disease of the newborn (HDN) due to Rh-D immunisation has become an 
infrequent complication of pregnancy, all women who become sensitised can, on all 
subsequent pregnancies with a Rhesus positive baby, be effected (Tiblad et al, 2013). Once 
anti-D antibodies are produced by the mother they remain in the system forever. Tiblad et al., 
(2013) in a retrospective cohort study analysed the timing of Rh-D immunisation in pregnancy 
and the consequences for the existing, and subsequent pregnancies. The objective was to 
design an optimum antenatal screening and prevention program. The reliability of this study is 
in question due to the fact that only 290 Rh-D immunised women were included. All women in 
the study had access to antenatal anti-D following a PSE and received postnatal anti-D 
following the birth of a Rh-D positive baby. Although the study had small numbers it found that 
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at least half of the cases of Rh-D allioimmunisation could potentially have being avoided by 
the administration of routine antenatal anti-D prophylaxis (RAADP) at the beginning of the 
third trimester. These findings give us valuable insight into the potential benefits of RAADP. 
This was further supported by the BCSH guideline (Qureshi et al., 2014) who recommended 
that routine RAADP should be regarded as a separate entity and administered regardless of, 
and in addition to, any anti-D that may have been given previously for a PSE.  
2.3.3 Implications for the Administration of Prophylactic Anti-D.  
There is strong evidence that RAADP prevents sensitisation in pregnant Rh-D negative 
women (Turner et al., 2012). Different prospective studies and clinical trials explore the use of 
a prophylactic one or two dose regimes (MacKenzie et al., 1999; MacKenzie et al., 2004). 
These studies exhibited a reduction in the incidence of maternal sensitisation using RAADP 
but there is no direct comparative data available that evaluates the efficacy of the single dose 
versus the two-dose regime (Qureshi et al., 2014).  The choice of the one or two dose regime 
may have significant impact on the planning of antenatal visits and the local budgets  
(MacKenzie, 2004). A primary concern is weighing up the risks and costs of administration of 
anti-D against the benefits and morbidity associated with non-administration.   MacKenzie et 
al. (2004) in a prospective study evaluated the two dose regime. This study acknowledged the 
effective period following anti-D administration is 42 days. In theory, to justify the use of a 
second RAADP at 34 weeks, is in order to cover the post-mature babies.  Laboratory studies 
did not confirm any clear advantage to this practice (Fyfe et al., 2014). MacKenzie (2004) 
supported this when he found no data that provided any evidence of differences in clinical 
efficacy between the different dose regimes. Indeed there is no internationally agreed policy 
on the correct dosage regimens to follow. MacKenzie did note that the rate of compliance with 
a one dose regime was greater. This led to the recommendation of a single-dose regimen as 
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it was likely to be simpler and lead to fewer errors in administration. Tiblad et al. (2013) in a 
retrospective study recommended from its findings to also use a one dose regime in 
gestational week 28-30 selectively to all Rh-D negative women. In England, the one dose 
regime is given as part of routine practice across the NHS (RCOG, 2011). 
It is also not enough to understand that we need to administer anti-D, we also need to ensure 
that we are providing a therapeutic dose in order to be successful (Koelewijn et al., 2009). In 
this study the authors found that there was merit in performing a Kleihauer test. This is a 
blood test used to measure the amount of fetal haemoglobin transferred from the fetus to the 
maternal bloodstream. Koelewijn et al., (2009) concluded that following a PSE, it was unlikely 
that the fetal blood loss that would extend beyond 1ml. Urbaniak & Greiss (2000) suggests 
that the general principle is that 100iu of anti-D will provide protection against 1ml of Rh-D 
positive fetal red cells. Currently in practice the dose administered is 1500 IU which protects 
against 15mls of fetal Rh-D positive cells. If the Kleihauer test results show a fetal blood loss 
exceeding 12mls than an additional “flow cytometry test” (Appendix 4) is performed in order to 
accurately determine the amount of extra anti-D that is required. The Kleihauer test is only 
required in such events that it is considered that potentially more than 15mls of fetal Rh-D 
positive cells will enter the maternal system. Examples of such events are following delivery 
and a large antepartum haemorrhage. The use of the Kleihauer test is not recommended in 
the administration of RAADP as it seems highly improbable that an unprovoked transplacental 
haemorrhage during the antenatal period is likely to exceed 15mls (MacKenzie et al., 2006).  
It would appear prudent to examine the economic aspects of introducing RAADP. Failure to 
prevent Rh-D sensitisation and manage neonatal HDN resulted in 114,100 avoidable 
neonatal deaths and many others growing up with disabilities on a global scale (Bhutani et al., 
2013). Chilcott et al. (2004) in a cost effectiveness analysis found that routine antenatal anti-D 
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prophylaxis provides a cost effective intervention to women who are Rh-D negative in 
preventing HDN. Further literature recommends that prophylaxis worldwide should be 
achieved as a matter of priority (Zipursky & Paul, 2011). 
Anti-D is recognised as a blood product and so requires the same traceability measures as 
with any other blood products.  By the late 1990’s there was growing anxiety among people in 
England in relation to possible infection from the administration of blood products. Some 
preparations previously used for Rh-D prophylaxis were withdrawn due to concerns relating to 
Creutzfeldt-Jakob disease (CJD) transmission (MacKenzie et al., 2006). This led to an 
increase in refusals among women when receiving RAADP from 0.8% to 3.5% (Qureshi et al., 
2014). In acknowledgement of the benefits of RAADP work remains ongoing in the 
development of recombinant antibodies in order to continue to protect against Rh-D 
sensitisation (Urbaniak & Greiss, 2000). 
The implications of administering RAADP on the neonate were also considered in a study 
(Dillon et al., 2011). This retrospective review aimed to look at the effect RAADP had on the 
Direct Coombs Test (Appendix 5) in the neonate and the subsequent requirement for 
phototherapy. The study concluded that there was an increase in direct coombs test (DCT) 
positive results from 1.5% to 2.3% following the introduction of RAADP which subsequently 
may result in an increase number of unnecessary bilirubin levels and phototherapy 
commenced in the neonate. The need for phototherapy only seemed to be significant in those 
neonates with high DCT levels. This paper is worth considering in an organisational context 
following the introduction of RAADP as a potential addition to the admission rate of the 
neonate to the special care baby unit for invasive monitoring and potential phototherapy. The 
causative factors for hyperbilirubinemia in the neonate is multifactorial and cannot always be 
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associated with high DCT levels. Others factors include ABO/Rh Group, ethnicity, and 
breastfeeding. 
2.3.4 The Importance of Education 
Despite the fact that the value for using anti-D has been acknowledged since 1969 more 
recent figures highlight the rise in errors occurring in the administration of anti-D (Hurrell, 
2014). In a UK-wide report it was acknowledged that the risk in errors occurring form 
transfusions had dramatically increased from 67 events in 2004 to 354 events in 2013 
(Bolton-Maggs & Cohen, 2013). Some of these findings were associated with the unsafe use 
of anti-D. Lack of knowledge among healthcare providers in relation to when and how anti-D 
should be administered seems to be the main problem (Hurrell, 2014).  
Bolton-Maggs et al. (2013) carried out a retrospective review of cumulative reporting to the 
UK haemovigilance scheme (Serious Hazards of Transfusion (SHOT)). This retrospective 
review reviewed the SHOT database from 1996 to 2011 in order to highlight the errors 
associated with the use of anti-D immunoglobulin in Rh-D negative women. The authors 
concluded that women and babies continue to remain at risk of sensitisation due to 
unavoidable user errors. This was further supported by a paper written by Hurrell (2014) who 
suggested that confusion remains around when and how it should be administered which 
continues to put women and babies at risk. As a result of this further education and training is 
an absolute necessity. This education also needs to be on-going (Hurrell, 2014). Bolton-
Maggs & Cohen, (2013) further recommend the use of a local checklist to help further reduce 
errors. The writer considered this when developing the project plan for this initiative. Finally to 
consolidate education around the administration of anti-D RCOG, (2011) recommends that 
information leaflets should also be made available to pregnant women to help with the 
informed consent process. 
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2.4 Implications for the Project 
The studies have shown the value of administering prophylactic anti-D to Rh-D negative 
women in pregnancy (Chilcott et al., 2004; Crowther et al., 2013; Fyfe et al., 2014; Hurrell, 
2014; Kumpel, 2006; Liumbruno et al., 2010; Pilgrim et al., 2009; Turner et al., 2012; 
Urbaniak & Greiss, 2000). These studies suggest offering RAADP to women in the third 
trimester at around gestational week 28-30. Education programs are required prior to 
implementation to increase knowledge and understanding of anti-D administration. The writer 
considered the introduction of an anti-D documentation checklist to further support staff with 
implementation. The practicalities of implementation need to be considered in chapter 3 to 
ensure success of the project with minimal disruption to existing services. 
2.5 Summary and Conclusion 
The purpose of this literature review was to develop a greater understanding and examine the 
role of prophylactic anti-D in pregnancy. Following an extensive review of the literature the 
writer acquired the theoretical understanding that was required to direct the organisation 
development project. Rh-D allioimmunisation in pregnancy continues to create a risk. The 
writer believes that there is sufficient evidence to support the use of RAADP as it has been 
shown to reduce the incidence of sensitisation and hence the risk of HDN. The introduction of 
prophylactic anti-D into a healthcare setting requires clear guidance for practice and in the 
writer’s opinion, and a structured educational programmes to ensure compliance. Chapter 3 
provides an in-depth analysis of the methods and methodology used to inform and deliver this 
project. The writer will apply the HSE OD Model to help describe a consistent approach to the 
change management project. 
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Chapter Three: Organisational Development Process 
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3.1 Introduction 
This organisational change project involves the introduction of RAADP to all Rh-D negative 
women at 28 weeks gestation at Cavan General Hospital. While this project has a relatively 
small scope Jacobs et al. (2013) warns that even small projects are also prone to poor 
planning, disappointing results and unintended consequences that divert resources from 
operational tasks, disrupt well established routines, and “shatter the trust” of employees and 
businesses alike. It is therefore important to apply the same rigor to the development, 
initiation, implementation and mainstreaming of this organisational change as would be 
required in a larger project in order to ensure success (Jacobs et al., 2013). Change 
management is becoming an increasingly significant topic for project management research 
and practice (Pollack, 2015). There are many different organisational approaches that can be 
used to help drive this project. The writer will critically review some of these approaches in 
order to help determine which one will be most suitable for use in this project. 
3.2 Critical Review of Approaches to Organisational Development 
It is important to define change management. Creasey (2009) describes it as the process, 
tools and techniques used to manage the people-side of change to achieve a required 
business outcome. Over the years many people have developed change models to help 
understand the change process and undertake change management. One of the earliest 
models was developed by Lewin in the late 1940’s. He used a reductionist approach. He 
described a three phase planned organisational change that helped move people from the old 
state to a new state. The phases were unfreeze, change and refreeze. This was further 
developed by Kotter (1995) who described the eight steps of change (Figure 2). This model 
consists of eight steps which commence with creating a sense of urgency, building and 
guiding a team, creating a vision, communicating the vision and removing the obstacles to the 
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vision, creating short term wins, declaring victories and finally anchoring changes in the 
organisational culture. 
 
Figure 2: Kotter’s Eight Steps of Change 
Kotter’s model takes on a more structured approach making the assumption that there is a 
correct way of doing things. However, while useful it is very scientific and tends to overlook 
the human relations element to change management, the writer feels that the human relations 
are an important factor in the process improvement proposed. 
As organisational development models evolved over the years they took on a more action 
research approach and Senior (2002) described an organisational development model of 
change that incorporates every part of the organisation and the people that work there (Figure 
3). This model focuses on creating a vision for the future state, with emphasis placed on the 
change agent. The change agent is seen to be responsible for the driving the change forward.  
 
Figure 3: Senior and Swailles Organisational Development Model 
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In 2009 the HSE published “A Users’ Guide for Managing Change in the Health Service 
Executive” (HSE OD Model). While this also adapted an action-research approach, its base 
was grounded in an organisational approach, which placed a strong focus on the people 
aspects of change. It is combined with project management which helps bring structure and 
discipline to the process. The aim of this model is to provide a consistent approach to 
effective change that can be applied by leaders and managers across the whole system and 
at all levels. It outlines four stages of the project management lifecycle (Figure 4). The stages 
include initiation, planning, implementation and mainstreaming. 
 
Figure 4: HSE OD Change Model 
The writer has chosen the HSE OD Change Model to support the implementation of her 
project because it was felt to be the most suitable approach to use given that the health 
service constantly needs to react to both internal and external factors which help to govern its 
existence. 
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3.3 Rationale for using the HSE OD Change Model 
The rationale for using the HSE OD change model is that this model acknowledges the 
complexities associated within healthcare. Change is constant with new initiatives required on 
a daily basis. In fact Abrahamson (2000) suggests that organisations have to change in order 
to stay alive. The changes currently being experienced by the Irish Healthcare system include 
the establishment of new services and the reconfiguration of existing services in order to 
improve outcomes for the service user and the wider population (HSE, 2008). The HSE OD 
Model recognises how different elements of change are interrelated and are dependent on 
people changing. While resistance to change is inevitable Stroller (2010) acknowledged that 
despite our aversion to change, our lives depend on progress and innovation, which is at the 
core of change. Using this model addresses ways of managing change in an attempt to bring 
people along during the “Initiation phase”. 
3.4 The HSE OD Model 
3.4.1 Initiation 
The key component of organisational change is to have clarity and be specific about the 
process improvement initiative. The clarity and specifics of the project are established in the 
initiation phase. The initiation stage is important to the success of the project as it helps lay 
down the foundations for the initiative. The HSE OD Model (2008) describes the purpose of 
the initiation phase as being necessary in order to establish a sense of shared responsibility 
and helps scope out a solid foundation for successful change. Performing a GAP analysis 
(Appendix 6) helps to assist in the journey of change.  Kotter (2008) further suggests that it is 
also necessary to inspire a strong sense of urgency to the project. This supports a concept of 
readiness that is intended to provide change agents with a perspective of what they need to 
do in order to convince change recipients to buy into the organisational change (Armenakis & 
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Harris, 2009). It is important to understand the need for change in order to be able to offer 
appropriate communication support, dealing with employees concerns, and actively involving 
staff in the process. These key factors help reduce employee resistance (Gerwing, 2015). 
Ford et al. (2008) further acknowledges that the key to overcoming resistance is rather than 
suppressing contributions to change, we should ensure to engage in all of it. A power/impact 
matrix chart was developed in order to identify the stakeholders that were to be involved in 
the project (Appendix 7). A stakeholder is anyone who is likely to be affected, directly or 
indirectly by organizational change or a programme of change (Huczinski & Buchanan, 2001). 
A stakeholder analysis chart (Appendix 8) was drawn up to help determine the level of 
involvement that was required by the relevant stakeholders. The list of stakeholders were 
identified through the use of a “responsible, accountable, consulted and informed” (RACI) 
chart (Appendix 9) and the roles and levels of communication that would be required by the 
various stakeholders were acknowledged. The more important the stakeholder is to the 
success of the project, the more time and resources were devoted to maintaining their 
involvement.  
The purpose of the initiation phase is to build the foundations for effective change and to 
mobilise support across the organisation (HSE, 2008). The project began by drawing up a 
business case to present to the stakeholders (Appendix 10). The purpose of the business 
case was to outline the project in order to obtain approval for proceeding with the change 
effort (HSE, 2008). This is a high level plan and provides clarity about the purpose of the 
change, while also providing an understanding of why change is required.  In context it is 
considered with the end in mind rather than as a process in its own right (Covey,1989). The 
initial business case also included a summary of key risks to delivering the project. These are 
also at a high level but were further developed in the implantation plan with control measures 
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identified as the detail of the project unfolded.  The information outlined in the business case 
informed the subsequent development of the implementation plan. 
3.4.2 Planning  
The planning stage involves the specific detail in relation to the change and helps to create 
support for the change process (HSE, 2008). This involved bringing the key stakeholders 
together to present the business case and communicate the change initiative proposed. The 
purpose of the planning phase is to increase participation and engagement of the change 
process. Building an increased understanding of what the change is intending to accomplish 
and what it means to all those personally involved is vital to the success of the project. The 
business case was presented to the key stakeholders and approval for the project was given 
and commitment secured. 
3.4.2.1 Building Commitment 
Once commitment for the project is secured it is important to ensure that the whole 
organisation understands the vision, and is committed and supported in making the project 
delivery a reality (HSE, 2008). At this stage the focus is on engaging staff and raising 
awareness for the project, while affording them an opportunity  to explore the implications the 
project will have on their day to day operations (HSE, 2008). Blackman et al. (2013) highlights 
that there needs to be a readiness in the capacity of the organisation to work together, both 
within and across the organisation. 
The importance of choosing a team leader for the project was highlighted by Sirkin et al. 
(2005) where they suggest that a good team leader has good problem-solving skills, are 
results orientated, methodical in their approach, are organisational savvy, willing to accept 
responsibility for decisions, and while being highly motivated don’t crave the limelight. On 
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analysing the stakeholders and to ensure success for this project it was decided to allocate 
the chair of the steering committee to the Haemovigilance officer as she was the embodiment 
of these traits and was known and respected by all other members of the team. The change 
agent will have the commitment, drive and time to bring the change to its successful 
completion (Stonehouse, 2013).  
3.4.2.2 Determining the Detail of Change 
During the initiation phase it is important to identify the processes existing within the service 
that has to change while also holding on to what’s good. Involving key stakeholders in order 
to provide input was identified as being integral to determining the detail of change.  Focus 
groups were set up to discuss the new initiative and an observation study was carried out to 
look at the patient journey through the maternity outpatient clinics. The manager of the out-
patient department identified that the clinic in its existing form would need to be amended as 
the time required to administer anti-D to all Rh-D negative women at 28 weeks was 
undeliverable in the current context due to time restrictions. A solution to this problem was the 
development of a separate antenatal clinic dedicated specifically to the administration of 
RAADP. Discussions in relation to the project helped to identify to all that change was on now 
inevitable. 
Prior to the undertaking of this project all anti-D injections for use in the hospital were sourced 
through the Pharmacy. It became apparent at the outset that this was inappropriate as anti-D 
is a blood product and as such should go through the same traceability and governance as for 
all blood products. This was to be achieved by transferring all dispensing responsibilities of 
the product to the laboratory with clear guidelines to access, dispensing and traceability 
records of the product. However this caused initial concern to the senior medical scientist on 
the team as he felt that distribution of anti-D through the laboratory may be beyond the 
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training for on-call medical scientists who only have limited knowledge and training. The 
consultant haematologist agreed to further discuss this with a fellow colleague who had 
governance over the blood bank. Other issues arose in relation to the administration of anti D 
in general but they will only be discussed in this paper if it directly impacts on the 
administration of RAADP. 
3.4.2.3 Developing the Implementation Plan 
The purpose of this step is to provide a more detailed plan of how the vision will be achieved. 
This helps to further prepare the organisation for change (HSE, 2008). The implementation 
plan was developed (Appendix 11) in order to provide a more comprehensive outline of the 
project. The Plan, Do, See, Act (PDSA) cycle (Langley et al, 2009) was used as a guideline 
for completing the implementation plan (Appendix 12). The execution of a “strength, 
weaknesses, opportunities and threats” (SWOT) analysis (Appendix 13) further informed the 
development of the implementation plan by giving credibility to the chosen improvement 
project. A SWOT analysis gives the project purpose by providing relevance to the initiative 
while considering both internal and external influences. The implementation plan provided a 
brief overview of the purpose of the project. The what, who, when and where of the project 
was identified and proposed delivery dates attached. The resultant implementation plan 
described all the critical requirements that were to be in place at project start and remain so 
for project success. A detailed description of the risks identified and the control actions that 
may affect the project success or progress, were listed (Appendix 14). An impact analysis 
supports better decision making through a deep understanding of risk (RCSI, 2015). It also is 
continually referred to over the life of the project to ensure that the objectives are being met. 
Any issues that were identified helped towards making amendments to the process. A 
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detailed list of resource requirements were also added to give focus to exactly where the 
money was required, and for what purpose. 
The need for guidelines and supporting documentation was identified and a working group 
was set up to work on this. Their task was to develop the guidelines, create and design an 
anti-D checklist (Appendix 15), and finally a patient information leaflet that would provide 
supportive information to the woman prior to administration of RAADP.  
All communication in relation to the project was agreed to be through emails and regular 
structured meetings where agenda items, actions, responsibilities, and time limits were 
discussed and agreed under the guidance of the chairperson. An example of the minutes are 
shown in appendix 16. Having a structured communication plan is important to the project as 
it gives consistent information over several different stages of the project and provides clarity 
on what the issues are and who is responsible for actioning them with realistic timelines 
towards achieving them. It is important to establish from the outset that change is underway.  
During the implementation planning it was identified that there was a need to move the 
dispensing of anti-D from the pharmacy to the laboratory. The logistics of transferring the 
dispensing of anti-D from the pharmacy to the laboratory was discussed and a team set up, 
primarily made up of the laboratory staff, to work on this. The managers in the relevant 
departments would be allocated the task of organising the clinics to facilitate the delivery of 
RAADP. These were included as the initial tasks on the project plan. 
The need for a training programme was identified and the haemovigilance officer and the 
project manager were allocated to design presentations to roll out the training programmes in 
the implementation phase. These were to be used to provide training to all relevant staff. 
During this phase it is important to support those who will be responsible for the role out of the 
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project. This was to be done by developing their skills, knowledge and competencies to help 
facilitate them in the role out phase. The creation of a guideline and supporting 
documentation to inform their practice would further provide that support. Once the detail of 
the implementation plan was developed it was important that it was then communicated to all 
key staff in order to test some of the design details. Introductory education sessions were 
given to all healthcare professionals to whom the role out of RAADP had an impact on. This 
was to help prepare the teams that change was on the way.  
Any potential industrial relation (IR) issues were to be explored at this stage. Due to the fact 
that the provision of this service was perceived to be in the client’s best interest and also to be 
well within each health care professional’s scope of practice, no IR issues were anticipated. A 
decision was made by the project manager not to involve the trade unions as she did not 
anticipate a need. Armenakis & Harris (2009) discuss the importance of involving all change 
recipients in the diagnosis, interpretation, and remediation of change facing the organisation. 
The writer reflects that by not involving everyone in the course of this project was an 
oversight, with a potential flashpoint being avoided by chance, rather than a good 
communication plan.  
A detailed GANTT chart was completed which included details about roll out and go live dates 
(Appendix 17). Due to the nature of the project the process improvement element was not 
piloted. However the anti-D checklist was piloted for approximately 2 months prior to go-live to 
help determine reliability and efficacy of the document design.  
3.4.3 Implementation 
This stage is the implementation of the project plan. This is monitored constantly to ensure 
that it is adhering to the timelines.  
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The developed guidelines and supporting documentation to support the administration of anti-
D were ratified by the organisation. Patient information leaflets were drafted for approval by 
the key stakeholders before being ratified by the organisation and sent for printing. These 
information leaflets were also sent out to the “National Adult Literacy Agency” (NALA) for 
proof reading.  
 In order to be ready for the go-live date of 5/10/2015 the main training of the maternity staff 
began of 22/09/2015. This was advertised through the use of a colourful poster which was 
displayed in all key service areas (Appendix 18). It was also sent out on email to all those who 
had access. Training was provided alongside the acute service areas to facilitate the dropping 
in of staff while on duty. Priority was given to staff working in the out-patient department and 
the midwifery led unit followed by staff in the antenatal wards. Staff working in out-patients 
were also given direction on the administration of IM injections using the deltoid muscle as 
this was not part of their routine practice to date. Not all staff were in a position to attend the 
allocated study days so remaining staff were trained on an adhoc basis by the writer who was 
on duty on a daily basis and was in a position to do one to one sessions. By 22/12/2015 95% 
of maternity staff were trained. Reasons for incomplete training was due to staff maternity and 
sick leave. 
While it is important to follow the implementation plan not all the roll out dates were achieved 
and amendments had to be made. While it was desirable that the guideline was signed off 
prior to go-live and that was what was intended, unfortunately the Quality and Risk committee 
(Q&R) meeting due on the 01/09/2015 was postponed until later in the year making it 
impossible to get the guideline ratified and signed off before the go-live date. As the result the 
project went live with a working draft document to support staff. A ratified document 
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completes the governance process and without this there was an increased risk to the project 
(Qulaity Function Office of Quality and Risk, 2011). 
By late August the manager on the maternity ward agreed to pilot the anti-D checklist to help 
determine its value and user friendliness. The instruction on the use of this document was 
done initially at ward level and further consolidated in training. Although the chart looks “busy” 
the staff found it a valuable tool in helping to inform their practice particularly in relation to the 
administration of anti-D following a potential sensitising event (PSE). Issues that arose 
following consultation with staff was duplication of double signature sign off. This was proving 
to not only be labour intensive but its value to practice was questionable. The reasoning for 
the duplication was that staff were not only required to double sign the drug kardex but the 
checklist also. As a result of this it was decided to see if the new checklist with minor 
amendments could also have the ability to accommodate prescription and therefore remove 
the need for a drug kardex. This was amended but is still awaiting approval and sign off from 
the drug and therapeutics committee (D&T). A working copy of the checklist remains in use. 
In preparation for the roll-out both the CMM2 in the out-patient department (OPD) and the 
midwifery led units (MLU) undertook various procedures to identify women eligible for 
RAADP. As both the OPD and MLU were different departments the operational piece was to 
become slightly different. To reduce the risk of error all women at the first consultants visit in 
OPD, highlighted as rhesus negative, were given an appointment for the 28 week midwives 
clinic. This was accompanied by a patient information leaflet. A follow up appointment letter 
was also sent out to them approximately 2 weeks before their scheduled appointment. While 
the MLU took a similar approach the 28 week appointment was run as normal with the new 
added feature of administering RAADP. Prior to the go-live date both the CMM’s went through 
all the existing charts and identified all those who were around 28 weeks after the 05/10/2015. 
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These were then contacted and informed about the new initiative with an accompanying copy 
of the patient information leaflet. 
3.4.3.1 Implementing change 
The administration of RAADP commenced on 05/10/2015. The first clinic commenced in OPD 
on the 07/10/2015 with 5 women attending for RAADP. This clinic was supported by the 
project manager who was in attendance to ensure that all staff were happy with the agreed 
process and that no issues arose in the execution of the clinic. 
The women expected to the clinic had being identified and a block order for anti-D was issued 
to the lab the previous day. The midwife running the clinic in the afternoon collected the 
injections from the laboratory prior to starting the clinic. They were transported to the clinic in 
a freezer box. Each injection had a patient label attached. For confidentiality purposes the 
boxes were returned to pharmacy following administration for disposal.  
On the initial go-live date the third client seen had her booking bloods done by the GP. This 
meant that the blood group report did not have the hospital number included. BSCH 
guidelines state that the group report for authentication purposes requires 3 patient identifiers. 
As this blood report only contained 2 identifiers (name and date of birth) the lab could not 
issue the anti-D until the woman had her blood group retaken. This was done but caused a 
delay to the clinic.  As a result of this incident the staff relooked at attendees at subsequent 
clinics and identified those who had similar blood reports. Any women who was identified that 
would require a repeat blood test on the day was contacted and asked to attend for bloods 
prior to commencement of the clinic. This was to help reduce interruptions to the flow of the 
clinic. 
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3.4.3.2 Sustain momentum 
Within healthcare improvements and change are continuous with new initiatives constantly 
being introduced or updated. It is a challenge for all healthcare professionals to sustain 
momentum and enthusiasm for all new initiatives being developed. In order to ensure that this 
project rolled out successfully and became part of routine practice it was important to 
regularly keep contact with front line staff and continue to have committee meetings in the 
initial post implementation phase. At the post go-live meeting the midwife who was 
responsible for running the anti-D clinic was invited to attend. Doing this allowed her a forum 
to discuss issues that arose at frontline while also meeting with people who had the ability to 
sort out these issues should they be outside her remit. 
The implementation of RAADP revealed a lot of positive behaviours within the workplace. The 
midwifery staffs at frontline services embraced the new role, and not only actively participated 
in the rolling out of this initiative but with minimal supervision were capable of troubleshooting 
a lot of the minor issues that arose post go-live. As the clinic was held in a remote area of the 
out-patient department the staff, and in consultation with the ward manager, it was decided in 
the interest of safety, all women at increased risk would be administered RAADP at ward 
level. Women with a factor 8 deficiency and those who were at risk of anaphylaxis were given 
appointments to attend the maternity ward for injection administration. An anaphylaxis box 
was also kept in the outpatient clinic for emergencies and all staff received anaphylaxis 
training. 
Following the identification of the original cohort of women who were to require RAADP the 
CMM2 in outpatients in an attempt to reduce the risk of women being overlooked, considered 
different processes to reduce the risk of this occurring. All women were identified at the first 
consultants visit and an appointment was booked for them at this point. The RAADP 
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information leaflet was also given to the women at this point. Reminder letters were also sent 
out to them 2 weeks in advance of that scheduled appointment. The introduction of reminder 
letters was something that was not covered in the guideline but the CMM2 felt that this was 
an important additive to the process in order to ensure that no women were missed. 
Implementation of the project was now complete. 
3.4.4 Mainstreaming 
The purpose of this next stage is to focus on the success of the change effort (HSE, 2008). 
When introducing any change within an organisation the development team will help drive the 
project and ensure that what needs to be done gets done in order for the project to succeed. 
The true measure of success of a project is that on completion it becomes “the way we do our 
business”, and does so independent of the project team.  
3.4.4.1 Making it “the way we do our business” 
Al-Haddad & Kotnour,(2015) identify the importance of choosing an integrated approach to 
drive systematic, constructive change as well as addressing the consequences of making the 
change. These are important factors to consider when integrating the new behaviour, skill and 
work practices. The development of a separate clinic whose sole purpose was the 
administration of RAADP helped to re-inforce and support the new behaviour. Creating a 
separate clinic made it easier to transit to a new mindset that was required in order to execute 
a new way of doing business. 
The concept of this process improvement was such that decision making processes were 
very clear. This was enabled by the guideline and supporting documentation that was 
developed while also providing flexibility to staff to develop further practices that were of 
interest to the project. An example of this was when the manager of the out patients 
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department developed a diary that contained the name of all Rhesus negative women that 
were identified after the initial blood group. This diary was used to schedule their 28 week 
appointment and also served as a trigger to staff to send out the two week reminder letter 
prior to their appointment. Although this was not covered in the supporting guideline the 
manager seen these further practices as a way to improve efficiency and effectiveness of the 
service. 
This stage also identifies the need to acknowledge success and to take time to celebrate 
achievements (HSE, 2008). On an annual basis, our hospital runs a “Quality and Safety 
Awards” ceremony that celebrate initiatives that have being achieved within the organisation 
in various categories. The writer plans to submit this project as part of the “Quality Initiative” 
awards category in order to celebrate all the work that went in to achieving this project. 
3.4.4.2 Evaluating and Learning 
The purpose of this stage is to look back at the project and critically review its design and 
implementation (HSE, 2008). It is important to acknowledge if we have achieved what we set 
out to achieve and to prepare for the future by making it part of the way we do our business. 
Flexibility and openness to change is critical for the organisation to remain relevant and 
responsive (HSE, 2008). The writer critically looked at the process and the eventual end 
result and reflects on some aspects of the project that led her to question whether we were 
indeed relevant and responsive to the needs of the service user. As described previously, all 
women receiving antenatal care at out-reach clinics had to attend the main hospital at 28 
weeks as we could not provide anti-D injections off-site. The writer questions how user 
friendly this was to our clients as it meant they had an added burden of travelling for an extra 
clinic to the main hospital. The new national maternity strategy launched this year (DOH, 
2016) aims to deliver a large amount of the maternity services in the community over the next 
43 
 
ten years. It was remiss of this project team not to look at ways on how we as an organisation 
would be able to adopt to this when anti-D will be required for administration at community 
level. 
It is also important to discontinue any activity that no longer serves the need of the new 
organisational reality (HSE, 2008). Therefore on the 22nd April 2016, the anti-D team held 
their last meeting at which they formally handed over to the maternity practice development 
team for on-going review and responsibility. It was the recommendation of this committee that 
a repeat audit would be carried out in a year to determine was there any new cases of women 
who became Rh-D sensitised. 
In order to measure success of the project we need to evaluate the aims that were laid down 
in chapter 1. The methods and process of evaluation will be covered more in depth in chapter 
4. 
3.5 Summary and Conclusion 
The aim of this project was to introduce the administration of RAADP to all Rh negative 
women at 28 weeks gestation in a rural maternity hospital in Ireland. The writer followed the 
HSE OD Model to help provide structure to the project but also because this model places a 
strong focus on the people aspects of change. This process improvement was heavily reliant 
on people not only to buy in to the initiative but also be willing to change the way they do 
things and provide a service that would be beneficial to this cohort of women. 
The writer included the use of various analytical tools to help inform the process. These 
included the use of SWOT analysis, stakeholder analysis, RACI chart, PDSA cycle, GAP 
analysis, impact analysis and risk controls charts. These tools helped to identify the key 
stakeholders that needed to be involved in the project while also providing data to those 
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stakeholders to help inform the need for change. They were also used to develop the 
implementation plan which was used to deliver the project successfully and within the 
specified timeframe. 
This chapter concluded with a brief overview on the evaluation of the change. This will be 
discussed in more detail in chapter 4. 
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Chapter Four: Evaluation
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4.1 Introduction 
The project went live on 05/10/2015 and all Rh negative women attending the hospital now 
receive RAADP at 28 weeks. Evaluation of change is fundamental to the change process in 
order to assess whether the change is working in practice or not (Cork, 2005). How 
successful this project was can only be determined through evaluation. We need to specify 
the outcomes of care, by formulating the appropriate criteria and standards, and finally 
obtaining the necessary information in order to assess quality (Donabedian, 1988). Choosing 
what to evaluate in order to determine success is vital. De la Harpe & Kavanagh (2007) 
highlight that if we measure the wrong things in the wrong way, then wrong things may get 
done. 
Firstly we will look at some definitions that best describe what evaluation is in the healthcare 
setting. Lazenbatt (2002) describes it as: 
“A method of measuring the extent to which an intervention achieves its stated 
objectives.” 
Another valuable definition used by (Green & South, 2006) defines it as: 
“Determining the value or worth of a healthcare initiative against a standard of 
acceptability. To examine or judge.” 
The challenge for healthcare professionals is not only to identify what quality is but also to be 
able to apply some sort of measurement tool in order to evaluate whether we achieved that 
quality. Research provides healthcare professionals with standards that achieve quality, 
whereas evaluation is the tool to assess whether we achieved these defined goals. Health 
managers have a responsibility to ensure access of quality services to all of the population 
served by a service (Ovretveit, 2002). 
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The writer will firstly look at the significance of healthcare evaluation followed by a critique of 
some evaluation models that will be considered for use in this project. This will be followed by 
publishing the results found using the chosen model for evaluation and a plan of how these 
results will be disseminated to the wider team involved in the project.   
4.2 Significance of Healthcare Evaluation 
It is important as health managers that we are able to improve the performance of health 
services in order to deliver a quality service (De la Harpe & Kavanagh, 2007). Green & South 
(2006) outline the benefits of evaluating. They describe it as being necessary to help improve 
health programme implementation, establish whether healthcare interventions have worked, 
and provide accountability to funders. It also helps to increase support for sustaining or 
expanding an intervention, contributes to the scientific base for interventions, and has an 
impact on policy decisions. Evaluation helps to provide information that is important to the 
service provider to ascertain these benefits. 
It is also important to be clear on what we need to evaluate. De la Harpe & Kavanagh (2007) 
highlight that it is important that the right things must get measured in the right way if they are 
to underpin the right management decisions in order to improve healthcare performance. 
Ovretveit (1998) looks at further breaking down evaluation into interventions that we can 
evaluate. Interventions are treatments, services, policies, and change to an organisation. 
4.3 Evaluation 
It is important to understand what we need to evaluate in order to ensure that we can 
determine whether this project was a success or not. Finding out what has worked and what 
has not is essential for human performance improvement and organisational success 
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(Kaufman et al., 1995). The easiest way to do this is to link back to the aims and objectives of 
this project. 
4.3.1 Aims 
Aim 2 states that by October 2015 all Rh negative women attending Cavan General Hospital 
will receive RAADP as recommended by the national guidelines. The writer reflected on the 
best way of evaluating this and concluded that a single before and after design outcome was 
the best approach. This was to take place in the form of an audit. The measurable outcome 
was that all women received RAADP post go-live. It was identified that a way to do this was to 
go to the laboratory records. The laboratory staff have access to records that identify all Rh 
negative women attending the hospital. They could also track all dispensing of anti-D 
injections. 
Aim 3 was to design and deliver the education programme to support practitioners with 
knowledge. Program evaluation is the use of social research procedures to systematically 
investigate the effectiveness of social intervention programmes such as education and 
training (McNamara, et al., 2010). The writer looked at different models for evaluation. The 
CIPP (“context, input, process and product”) model (Zhang et al., 2011) is a popular 
evaluation tool in educational settings. Its core concepts are context, input process, and 
product evaluation, with the intention of not to prove, but rather improve the programme itself 
(Stufflebeam, 2003). However this model requires a lot of careful planning and multiple sets of 
data collection are required to use it successfully. Due to the time constraints attached to this 
project the writer concluded that the Kirkpatrick model was the one that best suited this form 
of evaluation (Figure 5). It also provided clear evaluation questions that suited the type of 
evaluation required for this project. 
49 
 
 
 
Figure 5: Kirkpatrick’s Model 
This model focuses on 4 keys outcomes through its clear focus on learner behaviour in 
relation to the training. The four outcomes are reaction, learning, behaviour, and results. The 
writer will use these as a guide to discuss the evaluation used for this project. 
Finally, Aim 4 was to produce a patient information leaflet to be given to all Rh negative 
women prior to the administration of RAADP. The checklist contains the question “Patient 
received Anti-D information booklet prior to anti-D administration”. This question will be 
included in the documentation audit and a yes response will be interpreted as success to this 
aim. 
4.3.2 Methods and Measures 
Aim Two: By October 2015 the unit will administer routine RAADP to all Rh negative 
women at 28 weeks gestation in order to be fully compliant with the National Clinical 
Care Programme guideline. 
It is important to decide how quality is to be defined. Specifying the outcomes of care, 
formulating the appropriate criteria and standards, and obtaining the necessary information 
are the necessary steps in the process (Donabedian, 1988). The writer reflected on how best 
to obtain data that would verify that all women received RAADP following delivery of the 
“Did the learners like the training programme?” 
“Did the learners learn the content?” 
“Did the learners deploy the learnings to the job?” 
“Did the implementation of the training programme impact business results?” 
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implementation plan. The laboratory technician generated a report from the computer 
software system used in their department. A sample population was chosen between 
05/11/2015 and 09/02/2016. This population was all those who had received anti-D during the 
specified timeframe. The writer acknowledges that this information is driven by demand and 
does not specifically reflect the distribution of anti-D injection for the purpose of RAADP. In 
order to refine the search, the technician then added filters to the report. The filters removed 
administration by ward which excluded surgical and accident and emergency departments. 
This left the out-patient department (OPD) and the midwifery led unit (MLU). The maternity 
was included in order to capture those high risk women who received RAADP at ward level.  
Aim Three: Design and deliver an education programme to support practitioners with 
knowledge in relation to the use and administration of RAADP by January 2016. 
This evaluation was also done in two parts. Firstly the writer used an evaluation form that was 
given out to every member of staff that attended for training. This would help to identify the 
reaction and learning behaviours of the attendees.  A total of 66 evaluation forms were 
returned for use in the evaluation. This evaluation form established the “reaction and 
“learning” component of the Kirkpatrick model. Outcomes are presented in Figure 3.  
In order to assess the impact and the outcome of the training (Kirkpatrick Model), the writer 
choose to review the documentation checklist that was designed for use in the healthcare 
setting. Compliance with using the document and its completeness was determined to be the 
measure of success of the training. The document was assessed in relation to completeness 
and application in practice. Compliance with the administration of RAADP, when required, 
was also assessed using an audit.  
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Aim Four: Produce a patient information leaflet to be given to all Rh negative women 
prior to the administration of RAADP 
 The distribution of the anti-D information leaflet prior to administration was chosen as a 
measure to determine that the learner did training to practice, and a determination that the 
training investment did, in fact, pay off and the learners did deploy learnings to the job.  
4.3.3 Results 
Aim 2: In order to confirm that all women who were eligible for RAADP were offered it, the 
writer had to carry out two separate checking systems. Firstly, the numbers of pregnant Rh-D 
negative women were identified using the clinic diary that was developed by the ward 
manager. Once a woman was identified as Rh-D negative, a chart sticker belonging to her 
was placed in the diary. The writer counted the number of Rh-D women using this diary. 
Secondly, an audit of the dispensing of anti-D from the laboratory was carried out.  A total of 
133 anti-D injections were dispensed by the laboratory. 52 of them were distributed to OPD 
which accounted for RAADP as anti-D is not administered in OPD for PSE. Two more 
injections were documented as being destroyed. This was accounted for by two maternal 
refusals who did not consent to the administration of RAADP.  A total of 19 RAADP were 
administered to the MLU. The resultant two figures were matched confirming that all eligible 
Rh-D negative women were offered RAADP demonstrating compliance with the national 
guideline. 
Aim 3: The following questions and responses from the training day evaluation form were 
entered on to an excel spreadsheet and presented as below (Figure 6). 
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Figure 6: Education Evaluation Outcomes 
The evaluation findings showed that staff were satisfied with the training and felt that it helped 
develop their skills and knowledge. 
Aim 4: The writer evaluated the compliance of the completion of the checklist to ensure that it 
was documented in the chart that the anti-D was given when required. This audit was 
performed by the writer supported by the maternity clinical placement coordinator in January 
2016. It consisted of reviewing ten charts that were randomly chosen for audit purposes. 
These charts were identified from the clinic diary in the MLU and the new anti-D diary that 
was now in use in the out-patients department (OPD). Once identified the charts were 
accessed from the chart room in the medical records and the new anti-D checklist was used 
to source the following data collected (Figure 7). The information was collected and entered 
into an excel spreadsheet for analysis. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
The programme was well organised 
The learning outcomes were clearly defined 
The programme content was relevant to my area of practice 
Class discussion was a valuable part of the programme 
The programme was helpful in developing my skills and 
knowledge 
The time allotted to the programme was sufficient 
Education Evaluation Outcomes 2015-2016 
Agree Strongly Agree Disagree Disagree Strongly 
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Figure 7: Documentation Audit Mid-Project, January 2016 
This audit using the same format was repeated in April 2016 for comparative results (Figure 
8). 
 
Figure 8: Documentation Audit Post Project, April 2016 
The second audit showed an improvement with 100% of RAADP given as required. In both 
audits 100% of women received the RAADP information leaflet prior to drug administration.  
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
RAADP given if required  
Checklist used 
Checklist complete 
Anti-D leaflet given prior to adminisatration 
Anti-D RAADP Audit  Jan 2016 
10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
RAADP given if required  
Checklist used 
Checklist complete 
Anti-D leaflet given prior to adminisatration 
Anti-D RAADP Audit  April 2016 
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4.3.4 Dissemination Plan 
The writer presented these finding to the anti –D meeting group at a meeting on the 13th April 
2016. A copy of the findings was also distributed via e-mail to all the key stakeholders 
involved in the project. It is further proposed that the finding will be presented at the weekly 
maternity audit meetings that take place in the hospital and which are attended by all 
members of the multi-disciplinary team. 
The final project will also be submitted to the Quality and Safety awards in June 2016 as an 
exemplar of a Quality Initiative. It is also hoped that following submission of this dissertation to 
the RCSI it will be published on e-publications, allowing access at a public level. 
4.4 Summary and Conclusion 
The aim of this process improvement was to introduce RAADP to all Rh-D negative women at 
28 weeks in a rural hospital in Ireland. In order to achieve this the writer set a number of 
objectives to help deliver this. They were to provide an education programme to assist 
practice and also introduce a new documentation checklist to provide guidance for 
practitioners with their decision making. 
Evaluation of this project was carried out in three ways. Firstly the writer completed an audit 
looking at data available from the lab to determine that all women who were eligible received 
RAADP as that was the overall aim of the project. The results of the lab audit showed that 
98% of women eligible for RAADP received it. The 2% who did not receive it were because of 
maternal refusal and not omissions. The writer reflects that the aim of 100% compliance may 
have been unrealistic when you feature in the need for woman’s consent.  
The education programme was evaluated using the Kirkpatrick model and found that the 
staff’s evaluation response was received favourably as they scored the evaluation as either 
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“strongly agree” or “agree” in relation to learning and satisfaction. The kirkpatick model 
ensured that the questions asked in the evaluation form were measureable and the writer felt 
that using this model gave focus to the evaluation. The impact and results of the Kirkpatrick 
were further evaluated by the use of an audit where the completion of the checklist and the 
distribution of the anti-D information leaflet were used as a measure of achievement of the 
objectives. In the second audit carried out in April 2016 100% of women who received 
RAADP received the information leaflet prior to the anti-D injection. The fact that the checklist 
was completed 90% of the time, (an omission of date and time was the reason for non-
compliance), was seen as evidence that the learners did indeed deploy learnings to the job. 
Overall the evaluation findings showed a successful outcome to this project. Outcomes 
showed that the project was introduced successfully and delivered what it set out to achieve 
in its objectives at the start of the project. Chapter 5 will draw together the overall findings of 
this project.  
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Chapter Five: Discussion an Conclusions
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5.1 Introduction 
Change is a consistent feature of health and social care delivery (HSE, 2008). Indeed many 
change models acknowledge the significance of the decision that a compelling need for 
change exists (Fernandez & Rainey, 2006; Kotter, 1996). In order to survive and prosper in 
the current climate Armenakis & Harris (2009) acknowledge that we must be knowledgeable 
about how to implement appropriate organisational change that will be embraced by the 
employees.  
The writer lead this process improvement using the HSE OD Model (HSE, 2008) for 
guidance. The motivation for using this model was clear to the writer as the process 
improvement that was proposed was to take place in a healthcare setting. This HSE OD 
Model is specifically adapted for, and culturally sensitive to, the Irish Health Service 
environment (HSE, 2008). It provides a consistent approach to change and is the only model 
that places a strong emphasis on people and staff. It is good from the prospective that it has 
been agreed by all public sectors, both departmental and industrial relations. Most importantly 
of all, the HSE OD Model shifts the focus to sustainability. When people share beliefs and 
values, they can coordinate their efforts and intuitively know what to do (Glouberman & 
Mintzberg, 2001). Having common values is a very important part of process improvement. 
Process improvements are not short term projects, but need to be embraced within the 
organisation, to becoming the new way of conducting business. Engagement is essential for 
overcoming barriers  to quality improvements (Nembhard & Edmondson, 2006). 
This was the first time that the writer used a model of any kind for the delivery of a project, 
despite having lead out on different projects in the past. Using the HSE OD Model for the 
most part was extremely helpful as it provided a step by step approach to follow when rolling 
out the project. Critically the writer felt that the model was very “wordy” and as a result didn’t 
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always provide the clarity that the process needed. There was a lot of reading required in 
order to get to the key points that was the overall requirement of the different stages of the 
process. The nature of the document secured certain rigidity to the process, which at times 
left no room for artistic interpretation and innovative application of new ideas. All that been 
said, it added validity to all stages of the project, and justified aspects of the process that were 
considered redundant by some members of the team, myself included.  
5.2 Project Impact 
Managers need to put support systems in place that allow employees the opportunity to 
empower themselves to flourish, thus increasing their own effectiveness as well as that of the 
organisation (Kane-Urrabazo, 2006). This project brought a change of practice to the 
organisation that relied on staff empowerment, which in turn was pivotal to the success of this 
project.  
5.2.1 Stakeholders 
The identification of key stakeholders in the Initiation Phase of the HSE OD Model (HSE, 
2008) was very helpful to the writer. By performing a stakeholder analysis chart (Appendix 7), 
this helped to identify how involved different people needed to be, and also how reliant they 
were on the success of the project. In the initial stakeholder analysis the writer identified the 
obstetrician as “Medium” interest, “High” influence. It was felt that attendance at the anti-D 
meeting was required by the obstetrician. However as the project developed, the obstetrician 
did not attend any of the meetings, and his absence did not seem to interfere with moving the 
project on. Although Huczinski & Buchanan (2001) states that a stakeholder is anyone who is 
likely to be affected, directly or indirectly, by organisational change, once they are identified, 
the level of subsequent involvement in the change process needs to be given careful 
consideration. On reflection, once the consensus was received that RAADP would be given to 
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all Rh negative women, the value of having an obstetrician in attendance to discuss the 
practicality and logistics of the roll-out did seem wasteful. 
This project facilitated teams, who don’t normally interact with each other, to come together 
for a common goal. For the most part the laboratory staff have little or no engagement with 
clinical staff except through phone communication. Initially there was hesitancy among the 
stakeholders to mix clinical staff with technical staff, as it was felt that the priorities among the 
groups would be in conflict.  Kotter & Schlesinger, (2008) suggests that not involving the right 
people can lead to not having all the information needed to bring about change correctly. This 
project afforded the teams with an opportunity to come together and develop a process that 
was designed to be efficient, safe and all inclusive. Regular meetings provided all of the 
teams with an opportunity to gain a better understanding of what each other did and 
personally I found it a very enlightening experience where I gained new insight into the 
governance and workings of other departments that I had not known previously.  
5.2.2 Practice 
Reorganisation is usually feared, because it means disturbance of the status quo, a threat to 
peoples vested interest in the jobs, and an upset to the well-established way of doing things 
(Kotter & Schlesinger, 2008). It is important to acknowledge this when introducing a new 
initiative. The majority of change that was required for this project was heavily reliant on one 
main department. This was the out-patients department (OPD). It is important to understand 
the dynamic of this department. This team have worked together for many years and the 
manager of this department has being in her role for the over 16 years. Services ran as they 
had done for over a decade. Schein (1984) acknowledges that a group culture exists when 
people have been together for long enough to have shared significant problems and have had 
opportunities to solve these problems. The writer herself having worked within the 
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organisation for over 20 years, although in varying roles, was very cognizant of the culture 
that existed in this department. It was for this reason that the importance of involving the team 
at an early stage to help develop the process was seen as integral to the success of this 
project.  
Prior to roll out of the project the writer was very clear in how she seen the operational 
element of this project working. It was understood initially that the administration of anti-D 
injections would be given as part of the routine antenatal clinics visits. Indeed in the MLU, 
where she worked, it was decided to give the injection as part of the routine visits. The 
development of a new clinic that was run solely for the purposes of administration of the 
injection posed the following problems. This clinic would become a single discipline clinic with 
midwives, in the current setting, unfamiliar with working in isolation. Problems identified by 
women at this clinic that required obstetric input would require the development of guidance 
for staff as to the correct pathways required to obtain obstetric input.  However, following a 
brainstorming session with the out-patient department staff it became clear that the process of 
anti-D administration at the clinic was undeliverable due to cited time constraints.  Real teams 
always find ways for each individual to contribute and thereby gain distinction. Indeed, when 
harnessed to a common team purpose and goals, our need to distinguish ourselves as 
individuals becomes a powerful engine for team performance (Katzenbach & Smith, 2003). 
Acknowledging the value of team participation and its value in project delivery the writer 
agreed to the development of a separate clinic and the development of practices that would 
support it. The option to develop a separate clinic dedicated to the administration of the anti-D 
injection was explored and agreed.  
As the implementation plan rolled out, staff in the out-patients department added certain 
practices to the process already defined in the guideline. Their reasoning for this was cited as 
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providing extra failsafe measures to avoid omissions in administration. The introduction of 
anti-D diaries and reminder letters were developed by the out-patient team. The introduction 
of an RAADP stamper to be applied to the antenatal visits section of the chart was developed. 
This was done by the manager in the team without consultation with the project team and as 
a result the use of these stamps was not used initially by the MLU staff. They were added to 
the process once it was identified that they were in use. This was to ensure consistency in 
practice in both departments. Glouberman and Mintzberg (2001) identified that the most 
powerful way to enhance mutual adjustment is to strengthen the standardization of norms. 
Although the writer embraced these new changes that were implemented, she reserved 
judgement as to the value these multiple steps that were now added to the process, finding 
that they only made the process more labour intensive. 
As part of this project the process of transferring the distribution of anti-D from pharmacy to 
the laboratory needed to be addressed. This became a large part of the project and at times 
slowed down the implementation plan. However the value of now receiving anti-D from the 
pharmacy is tenfold. The ability to track this blood product is much easier and subsequent 
audits performed were achieved with minimal time constraints. This has value in relation to 
efficiency and the ability to audit ones practice for quality and efficiency. 
5.2.3 Theory 
Introducing quality programs are examples of large scale interventions that are aimed at 
improving health care (Ovretveit & Gustafson, 2003). It is important to have a clear 
understanding of the project and its potential value to the organisation. This cannot be done 
without looking to the evidence in order to help support the change. The writer carried out a 
literature review of the evidence in relation to the administration of RAADP and came up with 
4 main themes. It is necessary to understand what anti-D is and why it is needed in a 
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healthcare setting. The need identified from the literature is what informed this project (Tiblad 
et al., 2013;  MacKenzie, 2004; Qureshi et al., 2014). The importance of timely administration, 
and the importance of education, were keys factors in successful compliance of 
administration of RAADP (Hurrell, 2014; Bolton-Maggs & Cohen, 2013; Bhutani et al., 2013; 
Turner et al., 2012;  MacKenzie, 2004; Koelewijn, et al., 2009; Urbaniak & Greiss, 2000). The 
literature review is what informed the project team and was used in conjunction with the 
business plan as the background to delivering the project to the key stakeholders for 
approval. 
The use of the HSE OD Model provided the writer with a structure that was to inform the life 
of the project. It was easy to use and provided guidance that was sequential and practical.  
The model was ideal for use in a healthcare setting because it places a strong emphasis on 
people and staff. 
5.3 Strengths of the Project 
There were many strengths to this project. Having working in this organisation for over 20 
years it is sometimes easy to believe that change is impossible. However, this project that if 
there is clear guidance and hunger for change that people, for the most part, are willing to 
provide a service that they are proud of. The writer is reassured that the service will stand up 
to any scrutiny and proclaim efficiency. 
The strengths of this project were that it was rolled out as part of a dissertation. This created a 
sense of urgency for the project and kept the things moving in a forward direction. This is 
essential to any change management (Kotter, 1996). The senior management team approved 
this initiative from the outset and never at any point in the process put any barriers or 
obstacles in the way of achieving completion.  
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The process of moving the dispensing of anti-D from the pharmacy to the laboratory was a 
challenging part of the project. However its successful transfer from one service to another 
proved highly beneficial when it came to evaluation. All dispensing of anti-D was logged on to 
the laboratory computer system. This allowed easy access to data when reviewing the 
service. Cross checking of maternal blood groups with administration of anti-D was possible 
using the same laboratory system.  
During the lifetime of the project there were changes to the project team. In November 2015 
the haemovigilance officer, who was chair of the anti-D meetings group, got a new job within 
the RSCI Hospital Group. The project manager took over her role as chair but in January 
2016 she too left her role in the organisation and took up a new post outside of the hospital. 
The strength of this project was that despite these changes there was minimal disruption to 
the project and it subsequently achieved what it set out to do.  
5.4 Limitations of the Project 
For the most part the writer felt that this process improvement was highly beneficial to the 
organisation. The evaluation methods that were applied to this project proved that indeed it 
was successful and achieved what it set out to achieve. Looking at the literature the evidence 
suggests that the reason for introducing RAADP was to ultimately reduce the risk of 
haemorrhagic disease of the newborn (HDN). This is more challenging to prove. Knowing 
whether the introduction of RAADP would in fact reduce the incidence of HDN goes beyond 
the lifespan of this project. It is a rare condition and would take several years before any data 
of sufficient quality would be available for analysis.  It was agreed at the last anti-D group 
meeting that an audit would be carried out in a year following commencement of RAADP in 
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order to determine if there were any new incidents of Rh-D allioimmunisations post 
implementation. 
On reflection the writer never addressed the fact that the women attending out-reach clinics 
had to attend the parent hospital at 28 weeks in order to receive this injection as it could not 
be given across sites. This was a limitation of the project that came to light only after the 
project rolled out. The new maternity strategy document (DOH, 2016) highlights the need for 
more women focused maternity care, with many services moving to community settings. 
There will be a need to deliver services in the community and issues like the delivery of 
RAADP will need to be achieved at community level, if we are truly to want to deliver a 
woman focused service.  
5.5 Recommendations 
The writer recommends that the next step in this process is to look at the ability of the service 
to be able to provide anti-D injections off-site. Having the ability to deliver this injection outside 
of the main hospital is a step towards making this a more woman friendly service. 
5.6 Summary and Conclusion 
This organisational development was to introduce RAADP to all Rh negative women at 28 
weeks, attending Cavan General Hospital. The writer used the HSE OD Model which 
provided structure to the project. The aims of the project were achieved and evaluated using 
different audits. A documentation checklist was designed to guide staff with administration of 
anti-D in general and an audit of this documentation showed good compliance with the 
document. An education programme designed to give a better understanding about anti-D 
was received positively by staff and helped to inform their practice. The women received an 
information leaflet prior to the administration of RAADP in order to help them make an 
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informed decision in relation to their care. The documentation audit showed 100% compliance 
with administration of this leaflet. Finally the laboratory showed that all women who were Rh 
negative were offered RAADP post project go-live and the reason for non-compliance was 
cited as patient refusal. This leads the writer to conclude that we must never forget that 
women have a right to refuse care and staff supported them in their decision to do so. 
The impact that this project has had on the organisation can only be seen as a positive one. 
Within the organisation midwives are now running a stand-alone clinic within the main 
maternity services. Although midwives in the MLU have been providing clinic services, this is 
the first time midwives have been providing stand-alone clinics as part of the main maternity 
services. The writer sees this as a step closer to further developing midwives skills to support 
the development of “midwifery supported care” as is recommended by the maternity strategy 
(DOH, 2016). Finally, it is the writers view that those involved in the project have come to a 
better understanding of different departments and how they work, which has improved 
working relationships overall. The next step in this project is now to look at the ability to 
deliver RAADP off-site. 
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Appendices 
Appendix 1: Potential Sensitising Events in Pregnancy (PSE) 
 
Potential Sensitising Events in Pregnancy 
 
 
 Termination of pregnancy (medical or surgical) 
 Evacuation of the uterus (medical or surgical) 
 Miscarriage – threatened or complete miscarriage 
 PV Bleeding in early pregnancy (depends on pain/gestation) 
 Molar pregnancy 
 Ectopic Pregnancy 
 Antepartum Haemorrhage 
 External Cephalic Version (including attempted procedure) 
 Chorionic villous sampling 
 Amniocentesis 
 Cordocentesis 
 Other in-utero therapeutic intervention/surgery (e.g. Intra Uterine transfusion/insertion of shunts etc) 
 Abdominal trauma (sharp/blunt, open/closed) or fall 
 Intrauterine Death 
 Stillbirth 
 Post Delivery – if RhD positive baby 
 
 
Pregnant Less than 12 weeks Gestation Anti-D required ONLY: 
 
 
 Molar pregancy (requiring surgical evacuation) 
 Miscarriage (requiring surgical or medical intervention) 
 Medical/surgical termination 
 Ectopic pregnancy (treated surgically or medically) 
 PV bleeding with moderate-severe pain 
(If any of these are present woman eligible for Anti-D from positive pregnancy test) 
 
 
Between 12 and 20 weeks Pregnant Anti-D is required When: 
 
 Evacuation of uterus (medical/surgical) 
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 Miscarriage – threatened /complete 
 Termination of pregnancy – medical/surgical 
 PV Bleeding – without pain (once/recurrent) 
 Molar pregnancy 
 Ectopic Pregnancy 
 Abdominal trauma/fall (sharp/blunt, open/closed) 
 Intrauterine Death 
 
Between 20 and 40 Weeks Pregnant Anti-D is Required When: 
 
 Any PSE event 
 28-30 – RAADP offered 
 Post delivery – RhD positive baby 
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Appendix 2: Level 2 Maternity Care 
Level 2 (Specialty Care) 
Definition Care of uncomplicated pregnancies with the ability to detect, stabilize, and 
initiate management of unanticipated maternal-fetal or neonatal problems that 
occur during the antepartum, intrapartum, or postpartum period until patient can 
be transferred to a facility which specialty maternal care is available. 
In addition to the above care of appropriate high-risk antepartum, intrapartum, 
or postpartum conditions, both directly admitted and transferred from another 
facility. 
Capabilities Birth centre capabilities plus 
 Ability to begin emergency caesarean delivery within a time interval that 
best incorporates maternal and fetal risks and benefits with the 
provision of emergency care. 
 Available support services including access to obstetric 
ultrasonography. Laboratory testing and blood bank supplies at all 
times. 
 Protocols and capabilities for massive transfusion, emergency release 
of blood products, and management of multiple component therapy. 
 Ability to establish formal transfer plans in partnership with a higher-
level receiving facility.  
 Ability to initiate education and quality improvement programs to 
maximize patient safety, and/or collaborate with higher-level facilities to 
do so. 
 Computed tomography scan and ideally magnetic resonance imaging 
with interpretation available. 
 Basic ultrasonographic imaging services for maternal and fetal 
assessment. 
 Special equipment needed to accommodate the care and services 
needed for obese women. 
Types of 
health care 
providers  
Birthing centre providers plus 
 Continuous availability of adequate number of midwives with 
competence in level 2 care criteria and ability to stabilize and transfer 
high-risk women and newborns who exceed level 2 care criteria.. 
 Midwifery leadership and staff have formal training and experience in 
the provision of prenatal nursing care and should coordinate with 
respective neonatal care services. 
 Obs-gyn available at all times 
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 Director of obstetric service is a board certified ogs/gyn with special 
interest and experience in obstetric care. 
 Anaesthesia services available to provide labour analgesia and surgical 
anaesthesia at all times. 
 Board certified anaesthesiologist with special training or experience in 
obstetric anaesthesia available for consultation. 
 Medical and surgical consultants available to stabilize obstetric patients 
who have been admitted to the facility or transferred from other 
facilities. 
 
Examples of 
appropriate 
patients (not 
requirements) 
Any patient appropriate for a birth centre, plus capable of managing higher-risk 
conditions such as 
 Term twin gestation 
 Trial of labour after caesarean section 
 Uncomplicated caesarean delivery 
 Severe preeclampsia 
 Placenta praevia with no prior uterine surgery 
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Appendix 3: Allioimmunisation  
Definition: An immune response generated by an individual in response following exposure 
to genetically different cells or tissues from a different individual of the same species. 
 
Appendix 4: Flow Cytometry Test 
 
Flow Cytometry Test: 
In biotechnology, flow cytometry is a laser-based, biophysical technology employed in cell 
counting, cell sorting, biomarker detection and protein engineering, by suspending cells in a 
stream of fluid and passing them by an electronic detection apparatus. It allows 
simultaneous multiparametric analysis of the physical and chemical characteristics of up to 
thousands 
 
 
Appendix 5: Direct Coombs Test  
 
Direct Coombs Test Definition: A test used to detect antibodies or complement proteins 
that are bound to the surface of red blood cells. A blood sample is taken and the red blood 
cells are washed and then incubated with anti-human globin (Coombs reagent). If this 
produces agglutination of red blood cells then the direct coombs test is positive as it confirms 
a visual indication that antibodies are bound to the surface of red blood cells. 
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Appendix 6: Gap Analysis 
 
 
Current State Future State Gap Identified Action 
No RAADP 
administered to 
Rhesus negative 
women at 28 
weeks gestation  
National guideline 
recommends the 
administration of 
RAADP 
Non-compliant with 
guideline 
All Rhesus negative 
to receive RAADP 
at 28 weeks 
gestation 
All women attend 
antenatal clinic 
where there is high 
waiting times  
A move efficient 
running clinic 
Time delays 
unavoidable due to 
current clinic 
process  
Run a separate 
clinic to administer 
RAADP 
Anti-D is dispensed 
through pharmacy 
A more robust 
traceability of blood 
products 
Non-compliant with 
regulations in 
relation to the 
dispensing of a 
blood product 
Anti-D is dispensed 
through the lab. 
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Appendix 7: Stakeholder Power/Impact Matrix 
 
 
Power Impact/Matrix 
Introduction of Routine Anti-D Prophylaxis for all Rhesus Negative Women (RAADP) 
attending Cavan General Hospital 
 
High Importance 
Low Influence 
 
 
 CMM OPD/MLU 
 
 Haematologist 
 
 
 Project Manager 
 
 Laboratory Staff 
 
 Haemovigilance Officer 
 
High Importance 
High Influence 
 
 DOM 
 
 
 
 
 
 Obstetric Consultants 
 
 
 
Low Importance 
Low Influence 
 
 NCHD’s 
 
 SHO’s  
 Rh Neg Women 
 
 
 Midwives 
 
Low Importance 
High Influence 
 
 
 GM 
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Appendix 8: Stakeholder Analysis Chart 
 
Stakeholder Analysis 
Name Interest/Impact Influence Resistance Responsibility Dependency on 
the project 
How to communicate Involvement  
GM  Low  High  Budget  Low  High Present business case 
and secure sign off.  
Email updates on project 
progress 
Approval for project to be 
given. 
Senior support if required 
Obstetricians  Medium High  Potentially have the 
power not to sign off 
on the project 
Low  High  Meetings and emails To agree to RAADP 
DOM  High  High  Resources  High  High  Meetings and emails Sign off  and support 
CMM2 Medium  Medium Labour intensive. 
Training 
requirements. 
 
High  High  Meetings and emails Updated regularly and 
involvement in the logistical 
roll out. 
Redistribution of staff as 
required 
Midwives Medium  Low  Labour intensive  Low  High  Through the CMM who 
will need to regularly 
update staff 
Brain storm with CMM to 
help with logistical roll out 
phase. 
Training  
Lab Staff Medium  Low  Labour intensive as 
the dispensing of 
Anti-D will become 
a new role for this 
group 
Low  Medium  Meetings and emails Audit responsibility and 
traceability of product. 
Dispensing of product 
Haemovigillance 
Officer 
Medium Low None anticipated  Medium  High  Meetings and emails Become chair of the Anti-D 
meetings. Help deliver 
training  
Rh Negative 
Women 
Low  Low  Potential refusal of 
consent for 
treatment 
Low  Low  Patient information leaflet 
and staff engagement 
None 
Haematologist  Low  Medium  None anticipated Low  Low  Meetings and emails To ensure that adherence 
to blood product 
administration 
requirements are fulfilled 
NCHD’s Low  Low  Omissions due to 
lack of awareness 
Low  Low  Through training and Obs 
Cons 
 
SHO’s Low  Low  Omissions due to 
lack of awareness 
Low  Low  Training and senior 
colleagues 
Prescribe drug as required 
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Appendix 9: RACI Chart 
 
 
     
 
 
 
 
 
 
 
 
 
 
80 
 
Appendix 10: Business Case 
Cavan Monaghan Hospital  
Business Case for Introduction of Routine Antenatal Anti-D Prophylaxis 
Purpose 
1. To provide an explanation for the need for introducing RAADP. 
2. To inform both the consumer and Health Care Professional that RAADP is available to all 
relevant Rhesus negative women. 
3. To educate all health care professionals in the use and administration of RAADP. 
 
Reasons 
 Prior to 1970, the development of Anti-D antibodies in pregnant women secondary to fetomaternal 
haemorrhage (FMH) was a leading cause of perinatal mortality and morbidity as a result of 
haemolytic disease of the newborn, (HDN).  
 The introduction of Anti-D immunoglobulin for use in post-natal immunoprophylaxis and 
prophylaxis following potentially sensitising events significantly reduced deaths due to RhD 
alloimmunisation and significantly reduced the incidence of seroconversion with Anti-D antibodies 
among RhD negative women. 
 Despite these advances there are still a small proportion of women who become alloimmunised 
either due to silent antepartum haemorrhage, or failure to administer adequate amount of Anti-D 
following sensitising events. Sensitisation is most common in the third trimester and during 
childbirth. 
 In 2008 NICE (UK) recommended the introduction of Routine Anti-D Antenatal Prophylaxis, 
(RAADP) in an effort to prevent particularly third trimester sensitisations. It is recommended that all 
non-sensitised RhD negative women should be offered a dose of Anti-D immunoglobulin at 28-30 
weeks gestation and this is now the gold standard of care in the UK. 
 The publication of the HSE Clinical Practice Guideline on the use of Anti-D also recommended the 
use of RAADP at 28-30 weeks gestation for all non-sensitised women and many maternity units in 
Ireland are in the process of implementing a RAADP programme. 
 Based on these recommendations and a request from Obstetric/Gynaecology clinicians an 
estimated cost for the implementation of such a project for all eligible RhD women was 
investigated. 
 
Options Considered for Project Delivery with Predicted Costs 
 
Cavan Monaghan Hospital Figures 
Year Number of women 
delivered 
Number RhD 
Negative women 
Percentage of RhD 
Negative women 
delivered 
2010  2007 301 15% 
2011 2015 323 16% 
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2012 1897 313 16% 
2013 1890 231 12% 
2014 1851 239 13% 
 
Anti-D Usage 2010 – 2014 (includes administration to Maternity & Gynae patients) 
Year No of Anti-D Ampoules Issued from 
Pharmacy 
2010  290 
2011 305 
2012 297 
2013 270 
2014 262 
 
 On average 14% deliveries per annum are to RhD negative mothers.  
 Based on the delivery data for the last five years, there will be an approximate average of 281 
women who will be eligible for Routine Antenatal Anti-D Prophylaxis per year, which is 
approximately 20 women per month, but this will vary depending on the amount of RhD negative 
are at 28-30 weeks gestation at any time and on the annual birth rate in Cavan General Hospital. 
 
Requirements 
 
Overall 
 Anti-D immunoglobulin – per annum   €20,372  
 Patient Information Leaflet costs – editing by NALA €230 
 Patient Information Leaflet costs – printing per annum €150 
 Anti-D Checklist – printing cost per annum   TBC 
 Midwifery                             0.25 WTE 
 Clerical       30 mins per week 
 Laboratory                  30 mins per week 
 
Expected project benefits 
There is currently sufficient evidence to demonstrate that by providing RAADP, the risk of Rh-D 
immunisation in the subsequent pregnancy can drop to a level of below 0.4% (Liumbruno et al., 2010). 
This has long term benefits to both mother and future babies. 
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Project Risks 
Risk 
ID 
Description of Risk Risk Assessment Risk 
Rating 
(I x L) 
Impact (I) Likelihood (L) 
1 As a result of lack of understanding of the value of the use of 
RAADP among clientele, there is a risk of poor uptake of the 
injection 
3 4 12 
2  As a result of lack of understanding with the use of RAADP 
among staff, there is a risk of inappropriate care delivery which 
may lead to non-compliance of administration 
4 3 12 
3 As a result of inadequate and undefined guidelines, there is a 
risk of key information being overlooked impacting on patient 
safety.  
4 4 16 
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Appendix 11: Implementation Plan 
Implementation/Project Plan for the Introduction of RAADP to Rhesus Negative Women 
at 28 Weeks at Cavan General Hospital 
Overview 
This project proposes to guide the maternity services at Cavan General Hospital in relation to 
the introduction of Routine Antenatal Anti-D Prophylaxis (RAADP) injection for all Rhesus 
Negative women attending the service. 
The vision is that “In line with best practice all eligible rhesus negative women will be provided 
with RAADP injection at 28 weeks gestation”. 
The scope is that “All women identified at booking visit, who have no existing anti-D 
antibodies, will be given an appointment at 28 weeks gestation to the midwives clinic where 
RAADP will be administered”. 
This project plan was proposed based on the recommendations outlined in publication of a 
National Guideline (Fitzgerald & Conneally, 2012). 
The following is a list of objectives set out to help achieve this. 
1. Establish and implement procedures to facilitate the implementation of RAADP by 
September 2015. 
2. By October 2015, all eligible Rh-D negative women will be offered anti-D at 28 weeks 
gestation in order to be fully compliant with the National Clinical Care  Programme 
guideline (Fitzgerald & Conneally, 2012).  
3. Design and deliver an education programme to support practitioners with implementing 
the services by January 2016. 
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4. Produce a patient information leaflet to be given to all Rh-D negative women prior to 
the administration of RAADP. 
5. Access the effectiveness of this initiative in January 2016 and April 2016. 
 
Implementation Details 
WHAT WHO WHEN WHERE 
Draw up RAADP guideline MB/WG 01/01/2015 PD 
Create anti-D checklist MB/WG 1/03/2015 PD 
Patient Information leaflet MB/WG 30/05/2015 PD 
Move dispensing of anti-D from pharmacy to lab EH/WG 05/10/2015 Lab 
Set up anti-D clinic for  OPD and MLU MF+MR/WG 16/09/2015 OPD/MLU 
Provide training session for all staff to include 
midwives, doctors, and laboratory staff. 
MR/MB/WG 22/09/2015 
-20/12/2015 
All depts 
Go-live with RAADP MR 05/10/2015 OPD/MLU 
Post go-live audit MR 01/03/2016 PD 
 
Performance and Quality Measures 
The quality measure to assess outcome will be through the use of audit. The checklist will be 
audited for compliance and the lab will perform an audit to ensure that all eligible women 
attended the service within he specified timeframe received RAADP.  
Resource Requirements 
Anti-D Costs 
 Approx 281 ampoules Anti-D immunoglobulin  €20,372 
85 
 
 Patient Information Leaflet costs – editing by NALA €230 
 Patient Information Leaflet costs – printing per annum €150 
 Anti-D Checklist – printing cost per annum  TBC 
 
Anti-D Clinic 
 Weekly clinic held in OPD every Wednesday afternoon. 
 Approx 5 women per week to attend 
 
Preparation for Clinic 
Clerical 
 Clerical support to obtain approx 5 Maternity notes  30 mins 
 
Midwifery 
 Check notes and complete first page Anti-D Checklist 1 hour 
 Pre-order Anti-D from laboratory    15 mins 
Required 1hr 15 mins 
 
Laboratory 
 Issue approx 5 doses of Anti-D & package for dispatch 30 mins 
 
Clinic 
Midwifery 
 HCA or midwife to collect Anti-D from laboratory 10 mins 
 HCA or midwife to return transport box to laboratory 5 mins 
Required 15 mins 
Required per woman: 
 Ensure woman eligible to receive   5 mins 
 Two person check pre-administration    5 mins 
 Preparation, administration & documentation  5 mins 
 Woman to stay in OPD for 15 mins post administration 15 mins 
Required 5 x 30 mins = 2hr 30 min 
 
Total Midwifery Requirement 
 Pre Clinic Preparation     1hr 15 mins 
 Clinic Time       2hr 45 min 
Total         4 hours   
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Total Clerical Requirement 
 Pull 5 maternity charts      30 mins 
Total          30 mins 
 
Laboratory 
 Issue approx 5 doses of Anti-D & package for dispatch 30 mins 
Total          30 mins 
 
 
Overall 
 Anti-D immunoglobulin      €20,372 
 Patient Information Leaflet costs – editing by NALA €230 
 Patient Information Leaflet costs – printing per annum €150 
 Anti-D Checklist – printing cost per annum            TBC 
 Midwifery                                      0.25 WTE 
 Clerical       30 mins per week 
 Laboratory      30 mins per week 
 
 
Impact Analysis and Risk Control 
See Appendix 14 
Communication and Engagement Plan 
All communication for this project will be through anti-D meetings and email with the relevant 
stakeholders. 
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Appendix 12: PDSA Cycle 
 
 
 
• DO • STUDY 
• PLAN • ACT 
CORRECT & STANDARDISE 
- Standardise practice 
- Look for ways to make the 
process more efficient  
INVESTIGATE 
-- Not providing RAADP currently  
- Anti-D dispensed form pharmacy 
-  Look at  options 
- Meet with lab staff 
               ENLIGHTEN & IMPLEMENT 
 
-- Move dispensing of anti-D to the 
lab 
- Provide RAADP to all Rh Neg 
pregnant women 
-Logistics of administration to 
women 
- 
 
EVALUATE & VALIDATE 
- Carry out an audit on compliance 
with RAADP 
- Carry out an audit on compliance 
with new documentation to 
support the use of RAADP 
-  Make improvements as 
necessary 
- Present findings to  key 
stakeholders-  
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Appendix 13: SWOT Analysis 
SWOT Analysis 
Introduction of Routine Anti-D Prophylaxis for all Rhesus Negative Women (RAADP) 
attending Cavan General Hospital 
 
 
Strengths 
 
 National Clinical Care Programme 
guideline recommendation 
 Strong evidence to support 
RAADP in the literature review 
 
 
Weaknesses 
 
 Requires involvement and 
changes across numerous 
disciplines 
 Initiative potentially labour 
intensive 
 Administration of the injection is 
single site only 
 
Opportunities  
 
 Improve patient outcomes among 
this client cohort 
 National recommendation 
 Strengthen multi-disciplinary 
relationships 
 
Threats 
 
 Limited staff resources 
 Added cost to the service 
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Appendix 14: Impact Analysis and Risk Control 
 
 
 
Risk 
ID 
Description of Risk Risk Assessment Risk 
Rating 
(I x L) 
Impact (I) Likelihood (L) 
1 As a result of lack of understanding of the value of the use of RAADP 
among clientele, there is a risk of poor uptake of the injection 
3 4 12 
2  As a result of lack of understanding with the use of RAADP among staff, 
there is a risk of inappropriate care delivery which may lead to non-
compliance of administration 
4 3 12 
3 As a result of inadequate and undefined guidelines, there is a risk of key 
information being overlooked impacting on patient safety.  
4 4 16 
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Risk 
ID 
Before 
risk 
rating 
Control action After risk 
assessment 
After risk 
rating           
(I x L) 
Risk reduction 
potential 
(before-after) 
Assigned priority 
Imp. 
(I) 
Like (L) 
1.1 12 Design and distribute patient information leaflet on 
the use of RAADP to clientele 
4 2 8 4 High 
1.2 12 Provide verbal explanation of the value of RAADP to 
support leaflet 
4 2 8 4 High 
2.1 12 Provide education and training to all key personnel 4 2 8 4 High 
2.2 12 Provide initial go-live support to staff 4 2 8 4 High 
3.1 16 Draw up a set of guidelines to support and direct 
practice in the administration of anti-D 
4 2 8 8 High 
3.2 16 Introduction of an anti-D multidisciplinary checklist at 
ward level to support standardisation and improve 
patient safety.  
4 2 8 8 High 
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Appendix 15: Anti-D Checklist 
 
CF-HV-0036 Cavan Monaghan Hospital 
Anti-D Administration Checklist Ed 00 
Checklist No…………………… 
 Complete form for every RhD Negative woman who is pregnant or post-delivery 
Date: 
Record date form commenced 
Event date 
 
Event date Event date Event date 
1. Gestational Age or 
Post-delivery (PD) 
   /40   PD  /40   PD  /40   PD  /40   PD  
2. What is the woman’s 
blood group?  
     (Check most recent group 
and antibody screen    
      result on the Laboratory 
‘Ward Look-up’) 
If woman is not RhD 
negative Anti-D is not 
required 
Result: 
 
Result: 
 
Result: 
 
Result: 
 
Date of test: 
 
Date of test: 
 
Date of test: 
 
Date of test: 
 
Checked by  
Signature: 
Checked by  
Signature: 
Checked by  
Signature: 
Checked by  
Signature: 
3. Has group and 
antibody screen   
been taken in this 
pregnancy?  
    (if no, G&A sample must be 
taken to confirm    
     blood & RhD group and 
antibody status)    
 Yes   No  
  Checked by  
  Signature: 
  Yes   No  
  Checked by  
  Signature: 
  Yes   No  
  Checked by  
  Signature: 
  Yes   No  
  Checked by  
  Signature: 
4. Does the woman 
have an immune 
Anti-D already?    
     (Check latest & previous 
group & antibody     
     screen results.) 
If woman already has an 
immune Anti-D antibody Anti-D 
 Yes   No  
  Checked by  
  Signature: 
  Yes   No  
  Checked by  
  Signature: 
  Yes   No  
  Checked by  
  Signature: 
  Yes   No  
  Checked by  
  Signature: 
Patient Name: ___________________ 
Date of Birth: ___________________ 
MRN:             ___________________ 
Or affix addressograph label 
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Potentially Sensitising Events (PSEs) <12 weeks - delivery 
Gestation LESS than 12 Weeks Required Actions 
If any of the following  present – see ‘Required 
Actions’: 
- Vaginal bleeding associated with severe pain 
- Ectopic or Molar Pregnancy 
- ERPC/Instrumentation of uterus 
- Medical or surgical termination 
1. Work through checklist 1-6 above 
to ensure woman is eligible for 
Anti-D 
2. Administer 1500iu Anti-D within 
72hrs of the PSE 
3. No Kleihauer Test is required 
Gestation 12-20 Weeks Required Actions 
For any potentially sensitising events: 
- Termination of pregnancy 
- Evacuation of uterus 
- Miscarriage (threatened/complete) 
- PV bleeding 
- Ectopic pregnancy 
- Abdominal trauma/fall 
1. Work through checklist 1-6 above 
to ensure woman is eligible for 
Anti-D 
2. Administer 1500iu Anti-D within 
72hrs of the PSE 
3. No Kleihauer Test is required 
Gestation 20 Weeks to term Required Actions 
For any potential sensitising events (irrespective of 
whether RAADP has been given): 
1. Work through checklist 1-6 above 
to ensure woman is eligible for 
Anti-D 
2. Take a Kleihauer test and group 
and antibody screen (do not wait 
for the result) 
3. Administer Anti-D immediately or 
within 72hrs of PSE 
3. Administer additional Anti-D if 
required   
   (Contact Consultant Haematologist 
for    
   advice) 
As above plus: 
- Chorionic villous sampling 
- Amniocentesis 
- Cordocentesis 
- External cephalic version   
  (including attempted    
  procedure) 
 
- Intra-utero therapeutic 
intervention (IUT etc) 
- Abdominal trauma 
(sharp/blunt, open/ closed) 
- Intrauterine death 
- Stillborn 
For continuous vaginal bleeding 1500iu Anti-D should be administered at a minimum of 6-
weekly intervals, (irrespective of detectable Anti-D) and a Kleihauer should be taken every 
two weeks to monitor if additional Anti-D is required 
is not required 
5. Does the woman 
require Anti-D? 
 Yes   No  
  Checked by  
  Signature: 
 
  Yes   No  
  Checked by  
  Signature: 
  Yes   No  
  Checked by  
  Signature: 
  Yes   No  
  Checked by  
  Signature: 
6. Has informed 
consent been 
obtained for 
administration of 
Anti-D? 
 Yes  No  
  Obtained by  
  Signature: 
 
Yes   No  
  Obtained by  
Signature: 
  Yes   No  
  Obtained by  
  Signature: 
Yes   No  
  Obtained by  
Signature: 
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Routine Antenatal Anti-D Prophylaxis (RAADP) 28-30 weeks 
 Required Actions 
RAADP to be administered between 28-30 weeks 
gestation (irrespective of whether Anti-D has 
been administered already for a previous PSE) 
 Work through checklist 1-6 above to check if woman 
is eligible for Anti-D 
 
1. Work through checklist 1-6 on page 1 
to ensure woman is eligible for Anti-D 
2. If eligible - take group and antibody 
screen prior to Anti-D administration 
(do not wait for the result) 
3. Administer 1500iu Anti-D 
 Intrauterine Death (IUD) > 20 weeks 
 Required Actions 
IUDs  
1. Give Anti-D immediately following the diagnosis of 
an IUD  
2. Give further dose of 1500IU Anti-D post delivery 
1. Work through checklist 1-6 on page 1 
to ensure woman is eligible for Anti-D 
2. Take G&A screen & review result prior 
to administration of Anti-D. 
3. Take Kleihauer test prior to the Anti-D 
administration 
4. Administer 1500IU Anti-D prior to 
delivery 
5. If no cord blood result available 
administer a further 1500IU Anti-D 
within 72hr of delivery 
Does Kleihauer test/flow cytometry indicate that 
further Anti-D is required? 
 
1. Work through checklist 1-6 on page 1 
to ensure woman is eligible for Anti-D 
2. Administer more Anti-D (1500IU 
covers a 12ml bleed) Additional Anti-D 
dosage based on 125iu/ml 
AT DELIVERY  
 Required Actions 
Cord blood & Kleihauer must be taken at every 
RhD negative mother’s delivery 
Either: 
 Cord blood group of baby confirms baby blood group 
as RhD positive 
Or 
 No cord blood sample available 
1. Work through checklist 1-6 on page 1 
to ensure woman is eligible for Anti-D 
2. Take Kleihauer test ideally within 40-
60 mins of delivery, (max 2hrs) 
3. Take cord bloods for group and 
antibody screen. 
4. Administer 1500iu Anti-D within 72hr 
delivery 
Does Kleihauer test/flow cytometry indicate that 
further Anti-D is required? 
1. Work through checklist 1-6 on page 1 
to ensure woman is eligible for Anti-D 
2. Administer more Anti-D (1500iu covers 
a 12ml bleed) Additional Anti-D dosage 
based on 125iu/ml (Consultant 
Haematologist can be contacted for 
advice). 
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RECORD OF ANTI-D ADMINISTRATION 
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS 28-30 WEEKS 
 
Date:                               Gestation:          /40 
 
Patient Received Anti-D Information Booklet prior to Anti-D administration       Yes    No  
Patient gives verbal consent to Anti-D administration                                      Yes    No  
 
Group and Antibody screen taken prior to Anti-D administration                       Yes    No 
 
Anti-D prescribed on Medication Chart                                                            Yes    No 
 
Details on ID band match details on front of form, box label & Lab issue form    Yes    No 
 
Anti-D Batch No 1. Administered 
2. Checked by: 
Signatures 
1. Administrated 
2. Checker 
Printed Name 
Date of 
Administration 
Time of 
Administration 
 
 
1. 
2. 
1. 
2. 
  
If Anti-D not given at 28-30 weeks, please state reason/s: 
ANTI-D FOR A POTENTIALLY SENSITISING EVENT (<12 weeks – delivery) 
 
1. Date:                                     Gestation:       /40     
 
Start of sensitising event:   Date:                                  Time:                   . 
Reason for Anti-D:      Miscarriage        Bleeding during pregnancy  
                                    Trauma            Other Reason (please specify)_______________ 
 
Group and Antibody screen taken prior to Anti-D administration                      Yes    
No  
<20 weeks gestation – no Kleihauer Test required                                          Yes    No 
 
>20 weeks gestation – take Kleihauer Test prior to Anti-D administration         Yes    No 
 
 
Patient Received Anti-D Information Booklet prior to Anti-D administration           Yes    
No  
Patient gives verbal consent to Anti-D administration                                           Yes    
No 
Anti-D prescribed on Medication Chart                                                                Yes   
No  
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2. Details on ID band match details on front of form, box label & Lab issue form   Yes    
No  
Anti-D Batch No 1. Administered: 
2. Checked by: 
Signatures 
1. Administrator 
2. Checker 
Printed Name 
Date of 
Administration 
Time of 
Administration 
 
 
1. 
2. 
1. 
2. 
  
3. Kleihauer Result: _________ mls 
    Is Kleihauer  8mls? Yes*  No  
 
Result checked by: 
Signature: Date:   
If Kleihauer result  8mls may require flow cytometry +/- additional Anti-D refer to SOP CP-HV-0015 
*If Kleihauer result  8mls repeat Kleihauer test at 72hr/48hr post admin IM/IV Anti-D 
4. Repeat Sample taken Yes  No  
   Result: _________ mls 
 
Result checked by:  
Signature: Date:   
 
 
ANTI-D FOR A POTENTIALLY SENSITISING EVENT (<12 weeks – delivery) 
                                                                                        
1. Date:                                     Gestation:       /40     
 
Start of sensitising event:   Date:                                  Time:                . 
Reason for Anti-D:      Miscarriage        Bleeding during pregnancy  
                                    Trauma             Other Reason (please specify)_______________ 
 
Group and Antibody screen taken prior to Anti-D administration                      Yes    
No  
<20 weeks gestation – no Kleihauer Test required                                          Yes    No 
 
>20 weeks gestation – take Kleihauer Test prior to Anti-D administration         Yes    No 
 
 
Patient Received Anti-D Information Booklet prior to Anti-D administration           Yes    
No  
Patient gives verbal consent to Anti-D administration                                          Yes   No 
 
Anti-D prescribed on Medication Chart                                                                Yes   
No  
2. Details on ID band match details on front of form, box label & Lab issue form   Yes    
No  
Anti-D Batch No 1. Administered: 
2. Checked by: 
Signatures 
1. Administrator 
2. Checker 
Printed Name 
Date of 
Administration 
Time of 
Administration 
 
 
1. 
2. 
1. 
2. 
  
3. Kleihauer Result: _________ mls 
    Is Kleihauer  8mls? Yes*  No  
 
Result checked by: 
Signature: Date:   
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If Kleihauer result  8mls may require flow cytometry +/- additional Anti-D refer to SOP CP-HV-0015 
*If Kleihauer result  8mls repeat Kleihauer test at 72hr/48hr post admin IM/IV Anti-D 
4. Repeat Sample taken Yes  No  
   Result: _________ mls 
 
Result checked by:  
Signature: Date:   
 
 
POST DELIVERY 
1.                                                                              
Date of Birth:  Time of Birth:   Yes No Sample taken by: 
1. Cord bloods taken    
2. Kleihauer taken 45-60 mins post delivery (max 2hrs)    
 
2. Cord blood result: _____________  Signature:____________ Date:______ 
If baby’s cord blood result is RhD positive give mother Anti-D (if she does not already have an 
immune Anti-D) 
3. Kleihauer Result: _________ mls 
    Is Kleihauer  8mls? Yes*  No  
 
Result checked by: 
Signature: Date:   
If Kleihauer result  8mls may require flow cytometry +/- additional Anti-D refer to SOP CP-HV-0015 
*If Kleihauer result  8mls repeat Kleihauer test at 72hr/48hr post admin IM/IV Anti-D 
4. Repeat Sample taken Yes  No  
Result: _________ mls 
Result checked by:  
Signature: Date:   
 
5. Patient received information about Anti-D prior to Anti-D administration           Yes    
No  
    Patient gives verbal consent to Anti-D administration                                      Yes    
No  
    Anti-D prescribed on Medication Chart                                                           Yes    
No  
    Details on ID band match details on front of form, box label & Lab issue form   Yes    
No  
Anti-D Batch No 1. Administered: 
2. Checked by 
Signatures 
1. Administrator 
2. Checker 
Printed Name 
Date of 
Administration 
Time of 
Administration 
 
 
1. 
2. 
1. 
2. 
  
 
         If more than 4 doses of Anti-D are required during a pregnancy then please use an additional 
checklist. (Ensure each checklist is numbered) 
 
 
ANTI-D LABORATORY ISSUE FORM 
(AFFIX BELOW)
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Appendix 16: Anti-D Meeting Minutes Agenda 
 
ATTENDEES: 
APOLOGIES: 
Chairperson MB Gatekeeper MR 
Timekeeper MR Minute taker MB 
 
AGENDA MINUTES 
# Item/Detail Action Responsibility Time Limit 
1 Previous minutes Approved by those present MB  
2 Anti-D guideline Guideline approved by PPPG Group 
and awaiting final sign off by the 
Q&SEC. these can now be circulated 
as a working draft 
MB Before 15/10/2015 
3  Roll out date From Monday 5th October, with first 
RAADP clinic on Wednesday 8th 
October. 
Roll out will commence on 05/10/15 
even if anti-D is still stored in 
pharmacy 
MF 05/10/15 
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Appendix 18: GANTT Chart 
 
  
A GANTT chart mapping the project plan 
 
 Project from start  Feb Mar  Apr  May Jun  Jul Aug Sept Oct  Nov Dec  Jan Feb Mar Apr May 
1/02/2015 
Plan  
 
Gain buy in from 
key stakeholders 
 SMT 
 Midwifery 
team 
                
Draw up Business 
Case  
                
Develop 
Implementation 
plan 
                
Do 
 
Roll out training                 
Roll out 
implementation 
plan 
                
  
Study Perform audits                  
Discuss with key 
stakeholders 
findings of data 
collection 
                
Act Standardise 
Practice 
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Appendix 18: Anti-D Training Poster 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 HAVE YOU HEARD ABOUT THE 
NEW CAVAN MONAGHAN 
HOSPITAL ANTI-D GUIDELINE 
& THE INTRODUCTION OF 
ROUTINE ANTE-NATAL  
ANTI-D PROPHYLAXIS? 
(RAADP) 
 
THERE IS A NEW ANTI GUIDELINE 
& WE WILL BE GIVING PREGNANT RhD 
NEGATIVE WOMEN ANTI-D ROUTINELY 
AT 28-30 WEEKS 
To prepare everyone for the new changes & the introduction of the new  
Anti-D Checklist Mary Reilly will be holding education sessions as follows: 
 
DATE  TIME   VENUE 
22/09/15 15.00-15.45  SCBU Seminar Room 
22/09/15 15.45-16.30  SCBU Seminar Room 
23/09/15 14.00-14.45  Ante-natal Clinic Staff (venue to be arranged) 
23/09/15 15.00-15.45  Maternity Office 
23/09/15 15.45-16.30  Maternity Office 
28/09/15 15.00-15.45  SCBU Seminar Room 
28/09/15 15.45-16.30  SCBU Seminar Room 
29/09/15 15.00-15.45  Maternity Office 
29/09/15 15.45-16.30  Maternity Office 
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Appendix 19: Anti-D Poster 
 
The HSE OD Model2 was chosen 
to support the implementation of 
this project as it acknowledges 
the complexities associated with 
healthcare. It recognises how 
different elements of change are 
interrelated and are dependant on 
people changing.
The Kirkpatrick model was used 
to help design the evaluation 
questionnaire in order to assess 
the effectiveness programme that 
was developed for this initiative.
s
The writer evaluated the training 
programme.
Introduction & Background Evaluation 2
Since 2012 the HSE practice 
guideline in Ireland recommends the 
use of prophylactic anti-D (RAADP). 
It’s introduction into a rural hospital  
was in order to be compliant with 
this guideline. The reason for 
providing RAADP was to reduce the 
number of babies born affected by 
Haemolytic Disease of the Newborn 
(HDN). Anti-D injection is 
administered to women to prevent 
the maternal system developing 
antibodies against a rhesus positive 
baby, the cause of HDN.
The importance of developing an 
education programme to support the 
administration of RAADP was 
identified and rolled out as part of 
this process improvement.
The documentation checklist that 
was designed to support practice 
was audited in order to evaluate 
was the learning identified, 
translated into practice.
Findings showed that there was 
good evidence to suggest that 
learning was applied well to 
practice.
Aims & Objectives
The aims of this project was to 
introduce RAADP in a rural hospital 
using the following objectives:
1. Establish and implement  
procedures to facilitate the 
implementation of RAADP by 
September, 2015.
2. By October 2015, all eligible 
rhesus negative women will be 
offered anti-D at 28 weeks gestation 
in order to be fully compliant with the 
national guideline.1
3. Design and deliver an education 
programme to support practitioners 
with implementing the service by 
January, 2016.
4. Produce a patient information 
leaflet to be given to all rhesus 
negative women prior to the 
administration of RAADP
5. Assess the effectiveness of this 
initiative in January, and April, 2016 
Organisational Impact
Conclusion
The impact that this had on the 
organisation that processes were 
designed to support the 
administration of RAADP. An audit 
of the laboratory records showed 
that ALL women who were eligible 
between October 2015 and 
February 2016 were offered RAADP.
With the correct motivation and 
guidance, it is indeed possible to 
introduce change to a healthcare 
organisation. People working within 
the profession have a keen interest 
in putting patients at the centre of 
their service once they are 
supported with clear direction and 
leadership.
Methodology
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Figure 2: Kirkpatrick Model
Figure 1: HSE Change Model 2
Figure 3: Anti-D RAADP Audit 2016
Introducing Routine Antenatal Anti-D 
Prophylaxis for Rhesus Negative Women 
Mary Reilly
“Did the implementation of the training 
programme impact business results?”
“Did the learners deploy the 
learning's to the job?”
“Did the learners learn the 
content?”
“Did the learners like the 
training programme?”
0% 20% 40% 60% 80%100%
RAADP given if 
required 
Checklist used
Checklist complete
Anti-D leaflet given 
prior to adminisatration
Evaluation 1
0% 20% 40% 60% 80%100%
The programme was well organised
The learning outcomes were clearly defined
The programme content was relevant to my 
area of practice
Class discussion was a valuable part of the 
programme
The programme was helpful in developing 
my skills and knowledge
The time allotted to the programme was 
sufficient
Education Evaluation Outcomes 2015-2016
Agree Strongly Agree Disagree Disagree Strongly
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